# Generation Agent Outputs

## generation_metabolic
Cycle ID: 1

Hypotheses generated: H1, H2, H3, H4

---

**Hypothesis ID:** H1

**Hypothesis title:**  
Hypoxic MK methionine accumulation drives AMD1-mediated polyamine metabolism, shifting perivascular immune/stromal tone and contributing to medial thickening and vascular stiffening.

**PI instruction addressed:**  
Metabolomics-driven, direction-level: differential metabolite -> KEGG pathway-neighbor enzyme -> MK expression/differential -> broad downstream axis -> vascular remodeling. Uses user metabolomics (MK-sorted, PH vs control), Seurat scRNA-seq, and public dataset validation.

**Core directional hypothesis:**  
Increased methionine in PH-MKs drives AMD1-dependent polyamine (SAM, spermidine/spermine) production, which alters the pulmonary perivascular microenvironment—likely via immune modulation or direct vascular-wall signalling—augmenting hypoxia-induced medial thickening and vascular stiffness.

**Direction-level reasoning summary:**  
- **Data anchor:** MK-sorted metabolomics shows methionine up in PH vs control (log2FC 3.26); AMD1 is pathway-neighbor gene in Cysteine/methionine metabolism and Methionine salvage. Seurat: AMD1 expressed in 31.4 % of MKs (enrichment log2 1.35) and significantly upregulated in PH-MKs (log2FC 1.77, p=6.55e‑06).  
- **Biological interpretation:** Hypoxic MKs accumulate methionine, a precursor for SAM and polyamines. AMD1 catalyzes SAM decarboxylation, committing flux towards polyamine synthesis (spermidine/spermine). The strong MK enrichment and PH-up shift indicate hypoxia-induced metabolic reprogramming centred on polyamine metabolism.  
- **MK-linked pathway logic:** AMD1 is a rate-limiting enzyme for polyamine biosynthesis. Literature links mTORC1-AMD1 to polyamine metabolism in cancer, and polyamines (e.g., spermidine) regulate T‑cell differentiation and vascular cell proliferation. This positions MK AMD1 as a plausible metabolic rheostat in the hypoxic lung.  
- **Candidate downstream axes:** Polyamines secreted by MKs or released via extracellular vesicles could act (i) **immune-mediated** (e.g., promote Th17-like T‑cell or macrophage polarization), (ii) **direct vascular-wall** (stimulate SMC proliferation/fibroblast activation), or (iii) **EV/stromal** (alter matrix cross-linking).  
- **Remodeling logic:** Immune or stromal activation leads to medial smooth muscle hypertrophy/hyperplasia, perivascular collagen deposition, and reduced compliance—hallmarks of pulmonary vascular remodeling.  
- **Key uncertainty:** Whether MK-derived polyamines reach vascular target cells in sufficient concentration and whether AMD1 activity truly controls polyamine flux in hypoxic MKs (as opposed to alternative SAM-consuming pathways, e.g., methylation).

**Directional chain:**  
1. Hypoxia upregulates methionine import and/or methionine cycle flux in lung-resident MKs.  
2. Elevated methionine feeds SAM, which via AMD1 is partitioned toward polyamine synthesis (spermidine/spermine) rather than methylation.  
3. Candidate downstream axis: **immune‑mediated** (polyamines influence T‑helper/Th17‑like tone, macrophage activation) or **direct vascular‑wall** (polyamines act on SMC/fibroblasts) or **EV/stromal**.  
4. Broad cellular/tissue response: Perivascular inflammation, medial smooth muscle hypertrophy, and adventitial collagen accumulation.  
5. Contribution to remodeling phenotype: Medial thickening, muscularization, vascular stiffness.

**Candidate downstream axes:**  
- Plausible axes: immune-mediated (Th17-like/ macrophage), direct vascular-wall, EV/stromal.  
- Working model (provisional): immune‑mediated – polyamines modify local T‑cell or macrophage programs, amplifying vascular pathology.  
- Specific examples: spermidine, SAM, Th17 cell function, STAT3 activation, IL‑6/IL‑17 family cytokines, α‑SMA+ cell expansion.  
- MK-origin gap: MK polyamine secretion profile, stability, and diffusion in vivo not proven; AMD1 overexpression in MKs not directly measured at protein/activity level.  
- Falsification: MK‑specific Amd1 knockout or pharmacological AMD1 inhibition (e.g., SAM486A) should prevent hypoxia‑induced polyamine accumulation in lung, blunt perivascular immune changes, and reduce medial thickening. If AMD1 blockade fails to alter polyamine levels or vascular remodeling, the direction is falsified.

**Evidence basis:**  
- User-provided data:  
  - Metabolomics: methionine 3.26 log2FC up in MK-PH vs MK-control (*sFig6A Raw data.xlsx*).  
  - Seurat: AMD1 expression pct 31.44% in MKs, MK enrichment 1.353, PH-vs-control MK log2FC 1.77, p=6.55e‑06.  
- Public dataset metadata or analyzed public data: GSE289322 (bulk transcriptomics, case–control) provides a validation opportunity – check whether AMD1 is upregulated in PH lung tissue relative to control. If confirmed, supports tissue-level relevance.  
- Literature: AMD1/mTORC1 axis in polyamine metabolism (PMID 28658205); polyamines and EIF5A hypusination in cancer (PMID 38965534); broader roles in immuno‑metabolism.  
- Biological rationale: Polyamines are known regulators of cell proliferation and immune polarization; SAM/polyamine ratio influences methylation vs. polyamine synthesis.  
- Evidence status: Direct (metabolite change, MK gene expression, and differential expression in user scRNA‑seq); indirect (polyamine‑to‑vascular links from literature); public validation possible.

**Predicted observations:**  
- In MKs: Increased AMD1 protein/enzyme activity, elevated spermidine/spermine, and reduced SAM in PH-MK.  
- In recipient or tissue compartment: Elevated polyamines in PH lung tissue (confirmable by tissue metabolomics), perivascular polyamine-responsive immune signatures (e.g., Th17 markers).  
- In metabolomics or pathway activity: Lung tissue polyamine pathway flux increased; AMD1 inhibition reverses these changes.

**Experimental validation:**  
- Perturbation: MK‑specific Amd1 deletion (Mk-Cre x Amd1 flox) or systemic AMD1 inhibitor (SAM486A) in hypoxia model.  
- Model: Hypoxia‑induced PH mouse (HxSu or chronic hypoxia).  
- Readout: Lung polyamine levels (LC‑MS), perivascular immune cell composition (flow/IF), medial thickness, muscularization metrics, hemodynamics (RVSP, RV hypertrophy).  
- Expected result: Amd1 loss/inhibition blunts polyamine rise, reduces muscularization and stiffness.  
- Falsifying result: No change in lung polyamines or vascular remodeling despite efficient AMD1 blockade.

**Novelty:**  
First direct connection from MK methionine metabolism through AMD1‑polyamine axis to pulmonary vascular remodeling. AMD1 as an MK metabolic vulnerability in PH.

**Weaknesses:**  
Does not pinpoint the exact polyamine‑responsive cell type; relies on pathway logic (polyamine biology) rather than direct measurement of AMD1 product in MK secretome. Public dataset support absent until GSE289322 is queried.

**Revision relative to previous cycle:**  
Not applicable (first cycle).

**Priority estimate:**  
Score each from 1 to 5:  
- Directional specificity: 5 (clear metabolite → enzyme → pathway axis)  
- Data support: 5 (MK-specific metabolomics + scRNA-seq with strong significance)  
- Literature support: 4 (mTORC1/AMD1 papers; polyamine immunomodulation literature)  
- Novelty: 5 (MK-centric AMD1 axis in PH)  
- Testability: 5 (genetic/pharmacologic AMD1 manipulation in mouse PH feasible)  
- Overall generation priority: 5

**Explicit rejection filter:** Passes all checks (MK-specific, hypoxia-dependent, remodeling phenotype, not generic, testable, non-redundant).

---

**Hypothesis ID:** H2

**Hypothesis title:**  
MK Amd2 upregulation under hypoxia augments spermidine/spermine synthesis to cooperate with Amd1, reinforcing polyamine‑dependent vascular remodeling.

**PI instruction addressed:**  
Additional metabolomics‑driven hypothesis using Amd2, the isoform of AMD1, from the same methionine‑SAM‑polyamine pathway. Addresses potential functional redundancy/compensation.

**Core directional hypothesis:**  
Hypoxia‑induced upregulation of Amd2 in a subset of MKs provides a complementary polyamine synthetic capacity that, together with Amd1, elevates spermidine/spermine in the pulmonary niche, promoting perivascular immune activation and medial thickening.

**Direction-level reasoning summary:**  
- **Data anchor:** Methionine up in PH-MK; Amd2 is a methionine salvage/polyamine pathway neighbor gene. Seurat: Amd2 expressed in 4.4% MKs (enrichment log2 0.93), and significantly upregulated in PH-MK (log2FC 2.18, p=0.024).  
- **Biological interpretation:** While Amd2 expression is lower than Amd1, its hypoxia‑induced rise suggests an alternative or cooperative enzyme for SAM decarboxylation, potentially in a specialized MK subpopulation.  
- **MK-linked pathway logic:** Amd2 is a functional homolog of Amd1; both decarboxylate SAM for polyamine synthesis. Co‑upregulation of Amd1 and Amd2 could drive robust polyamine flux.  
- **Candidate downstream axes:** Same as H1: immune‑mediated, direct vascular‑wall, or EV/stromal. Polyamines influence T effector/memory balance and stromal cell proliferation.  
- **Remodelling logic:** Enhanced polyamine output promotes medial muscularization and perivascular matrix changes.  
- **Key uncertainty:** Whether Amd2 protein is active in MKs and its contribution relative to Amd1; low MK expression percentage may limit impact.

**Directional chain:**  
1. Hypoxia induces methionine accumulation and increases SAM availability.  
2. MKs upregulate both Amd1 and Amd2, diverting SAM into polyamine synthesis.  
3. Candidate downstream axis: immune‑mediated (e.g., shaping T‑helper or macrophage phenotypes) or direct vascular‑wall.  
4. Broad cellular response: immune cell recruitment/activation and vascular smooth muscle hypertrophy.  
5. Contribution to remodeling: medial thickening, muscularization.

**Candidate downstream axes:**  
- Plausible axes: immune-mediated, direct vascular-wall, EV/stromal.  
- Working model: Amd2 cooperates with Amd1 to sustain a polyamine‑rich microenvironment that favors inflammatory T‑cell or macrophage programs.  
- Specific examples: spermidine‑driven T‑cell skewing, macrophage M2‑like polarization.  
- MK-origin gap: Amd2 expression in only 5.9% of PH-MK; whether this is a distinct MK subset with unique secretome is unknown.  
- Falsification: Dual inhibition or KO of Amd1 and Amd2 in MKs should yield greater reversal of polyamine levels and remodeling than Amd1 alone. If Amd2 KO shows no additive effect, its role is dispensable.

**Evidence basis:**  
- User-provided data: Methionine up; Amd2 MK expression (pct 4.37%, enrichment 0.93, PH-up log2FC 2.175, p=0.0235).  
- Public dataset metadata/analyzed: GSE289322 could test if AMD2 is differentially expressed in PH lung; if absent, suggests MK‑specific role.  
- Literature: Amd2 gene context in muscle atrophy metabolomics (PMID 40768332), but no direct vascular literature.  
- Biological rationale: Two AMD genes may provide redundancy or fine‑tuning of polyamine synthesis in distinct cellular states.  
- Evidence status: Direct (gene expression differential) but limited by low MK percentage; inferred pathway role.

**Predicted observations:**  
- In MKs: Amd2 protein detectable in a subset of MKs, induced by hypoxia.  
- In tissue: Polyamine levels reduced more by dual Amd1/Amd2 inhibition than single.  
- In metabolomics: Lung spermidine/spermine correlate with combined Amd1+Amd2 expression.

**Experimental validation:**  
- Perturbation: MK-specific Amd2 knockout, dual Amd1/Amd2 knockout.  
- Model: Hypoxia PH mouse.  
- Readout: Lung polyamines, perivascular immune markers, vascular remodelling, hemodynamics.  
- Expected result: Amd2 loss alone mild effect; dual loss strong protection.  
- Falsifying result: Amd2 loss unchanged, dual loss no better than Amd1 alone.

**Novelty:**  
First consideration of Amd2 in MK biology; highlights gene duplication in polyamine pathway.

**Weaknesses:**  
Low basal and MK-specific expression; risk that Amd2 is not functionally relevant at protein level. No direct metabolite product measured.

**Priority estimate:**  
- Directional specificity: 4 (parallel rationale)  
- Data support: 3 (low expression percentage)  
- Literature support: 2 (sparse)  
- Novelty: 4  
- Testability: 4 (feasible with genetic models)  
- Overall generation priority: 3

---

**Hypothesis ID:** H3

**Hypothesis title:**  
MK methionine accumulation may alter DNA methylation via Dnmt3b, reshaping MK transcriptome and secretome to promote a pro‑remodelling phenotype.

**PI instruction addressed:**  
Exploratory metabolomics‑driven hypothesis linking methionine to Dnmt3b (methylation pathway neighbor) and potentially to an epigenetically driven MK state that impacts vascular cells.

**Core directional hypothesis:**  
Hypoxic MKs channel excess methionine into S‑adenosylmethionine (SAM) for DNA methylation via Dnmt3b, inducing a pro‑fibrotic or pro‑inflammatory MK transcriptional programme that affects perivascular fibroblasts and smooth muscle cells.

**Direction-level reasoning summary:**  
- **Data anchor:** Methionine up in PH-MK; Dnmt3b is a cysteine/methionine metabolism pathway neighbor gene, encoding a DNA methyltransferase. Seurat: Dnmt3b expressed in 2.62% MKs (enrichment 0.19), PH-vs-control MK log2FC 1.59 (p=0.212, not significant).  
- **Biological interpretation:** Although MK expression of Dnmt3b is low and not significantly PH-up, the methionine-SAM-methylation axis is a critical fate‑determining mechanism. Even modest epigenetic changes could prime MKs for altered cytokine or growth factor release.  
- **MK-linked pathway logic:** SAM is the universal methyl donor; Dnmt3b uses SAM for de novo DNA methylation. Methionine accumulation may drive hypermethylation at specific loci, silencing anti‑proliferative genes or activating pro‑remodelling factors.  
- **Candidate downstream axes:** Likely **direct vascular-wall** through MK-derived factors (e.g., TGF‑β, PDGF) or **EV/stromal** through altered MK exosome cargo.  
- **Remodelling logic:** Epigenetically modified MKs could secrete more pro‑fibrotic mediators, promoting fibroblast‑to‑myofibroblast transition and medial hypertrophy.  
- **Key uncertainty:** Low and non‑significant MK expression of Dnmt3b; no methylation data in user data. Methionine pool may not directly control Dnmt3b activity if SAM is diverted to polyamines.

**Directional chain:**  
1. Hypoxia raises methionine levels in MKs.  
2. Elevation of SAM pools may enhance Dnmt3b‑mediated DNA methylation in MKs.  
3. Candidate downstream axis: direct vascular‑wall (secreted growth factors/cytokines) or EV/stromal.  
4. Broad tissue response: Perivascular fibroblast activation, smooth muscle hypertrophy.  
5. Remodelling phenotype: Medial thickening, vascular fibrosis.

**Candidate downstream axes:**  
- Plausible axes: direct vascular-wall, EV/stromal, immune-mediated (altering gene expression of chemokines).  
- Working model (provisional): MK epigenetic reprogramming leads to secretion of pro‑fibrotic factors (e.g., TGF‑β1, CTGF).  
- Specific examples: hypermethylation of SOCS or DUSP genes could enhance STAT3 or MAPK signalling, amplifying MK cytokine output.  
- MK-origin gap: Dnmt3b expression and activity in MKs not validated; methylation changes in MKs not measured.  
- Falsification: MK‑specific Dnmt3b knockout or SAM synthesis inhibition (e.g., MAT2A inhibitor) should prevent hypoxia‑induced pro‑remodelling MK secretome. If MK epigenetic profile unchanged and secretion unchanged, hypothesis fails.

**Evidence basis:**  
- User-provided data: Methionine up; Dnmt3b expression low, not significant PH-up.  
- Public dataset metadata: GSE289322 may show DNMT3B expression in lung tissue; if absent, argues against tissue‑level relevance.  
- Literature: Methionine‑SAM‑methylation axis in immune cell differentiation; no vascular‑specific Dnmt3b reports in MKs.  
- Biological rationale: Epigenetic regulation of MK biology is established; Dnmt3b is involved in hematopoietic differentiation.  
- Evidence status: Speculative (metabolite link present, enzyme expression weak, no direct epigenetic data).

**Predicted observations:**  
- In MKs: Increased SAM/SAH ratio, global DNA hypermethylation at specific promoters, altered transcriptome (e.g., upregulated Ccl2, Tgfβ1).  
- In tissue: Pro‑fibrotic cytokine signature around MK‑rich regions.  
- In metabolomics: SAM consumption into methylation pathway.

**Experimental validation:**  
- Perturbation: Dnmt3b inhibitor (e.g., nanaomycin A) or Mk‑specific Dnmt3b knockout; alternatively, manipulate SAM levels with MAT2A inhibitor.  
- Model: Hypoxic PH mouse.  
- Readout: MK DNA methylation (RRBS), MK secretome analysis, perivascular collagen deposition, medial thickness.  
- Expected result: Reduced pro‑fibrotic MK output and attenuated vascular fibrosis.  
- Falsifying result: No change in MK DNA methylation at candidate loci or vascular phenotype.

**Novelty:**  
Links MK methionine metabolism to epigenetic control, a new paradigm in PH.

**Weaknesses:**  
Very weak supporting evidence for Dnmt3b in MKs; the hypothesis is exploratory and may be false.

**Revision relative to previous cycle:**  
Not applicable.

**Priority estimate:**  
- Directional specificity: 4  
- Data support: 1 (no significant MK expression change)  
- Literature support: 2  
- Novelty: 5  
- Testability: 4  
- Overall generation priority: 2 (low, due to weak data support)

---

**Hypothesis ID:** H4

**Hypothesis title:**  
MK-mediated retinoic acid degradation via Cyp26b1 blunts local retinoid signalling, relieving repression of inflammatory pathways and perivascular fibrosis.

**PI instruction addressed:**  
Metabolomics‑driven: retinoic acid (RA) up in PH-MK, path to Cyp26b1 enzyme, MK expression, candidate downstream axis.

**Core directional hypothesis:**  
Hypoxia upregulates Cyp26b1 in MKs to catabolize retinoic acid, reducing local retinoid‑mediated immune regulation or vascular quiescence, thereby permitting perivascular inflammation and medial hypertrophy.

**Direction-level reasoning summary:**  
- **Data anchor:** Retinoic Acid up in PH-MK (log2FC 3.44). Cyp26b1 is a direct compound-enzyme (retinoic acid hydroxylase) in Retinol metabolism. Seurat: Cyp26b1 expressed in 7.86% MKs (enrichment 0.73), PH-vs-control log2FC 0.91 (p=0.253, not significant).  
- **Biological interpretation:** RA is a potent immunomodulator and vascular stabilizer. MK accumulation of RA may reflect increased synthesis or decreased degradation. Cyp26b1 expression trends upward (though non-significant), suggesting MKs may attempt to catabolize excess RA; alternatively, hypoxia could upregulate Cyp26b1 to lower local RA, lifting immune suppression and promoting vascular remodeling.  
- **MK-linked pathway logic:** Cyp26b1 is the key enzyme for RA clearance. If MKs deplete local RA, they could create a pro-inflammatory niche (RA normally restrains Th17 cells and promotes Treg).  
- **Candidate downstream axes:** **Immune‑mediated** (loss of RA‑dependent Treg/Th17 balance, more Th17‑like inflammation) or **direct vascular‑wall** (RA signals directly quench SMC proliferation).  
- **Remodelling logic:** De-repression of inflammatory cascades or loss of anti‑proliferative signals in smooth muscle leads to medial thickening.  
- **Key uncertainty:** Low MK Cyp26b1 expression and borderline significance; RA levels may not reflect functional activity; Cyp26b1 may be induced in other cells, not MKs.

**Directional chain:**  
1. Hypoxia increases RA synthesis or impairs its degradation globally; MKs upregulate Cyp26b1 as a compensatory response, but insufficient, leading to net RA accumulation. Alternatively, MK Cyp26b1 may actively degrade RA.  
2. MK metabolic state: RA accumulation or RA degradation in MKs could alter MK function (e.g., autocrine effects) or local microenvironment.  
3. Candidate downstream axis: immune‑mediated (shift from Treg to Th17), direct vascular‑wall.  
4. Broad cellular response: Perivascular T cell infiltration, SMC proliferation.  
5. Remodelling phenotype: Muscularization, perivascular fibrosis.

**Candidate downstream axes:**  
- Plausible axes: immune-mediated (T helper balance), direct vascular-wall, unresolved.  
- Working model: MK Cyp26b1 reduces local RA, disinhibiting Th17‑like responses that drive vascular remodeling.  
- Specific examples: RA, IL‑17, IL‑6.  
- MK-origin gap: It is not certain that RA or RA‑degrading activity emanates from MKs; local RA may be produced by other lung cells.  
- Falsification: MK‑specific Cyp26b1 overexpression or knockout should alter lung RA levels and Th17/Treg balance, and impact vascular remodeling. No effect would negate the MK‑centric hypothesis.

**Evidence basis:**  
- User-provided data: RA up in PH-MK; Cyp26b1 MK pct 7.86%, PH‑up trend not significant.  
- Public dataset metadata: GSE289322 can probe CYP26B1 expression in PH vs control lung.  
- Literature: Retinoic acid pathway in vascular biology and immune regulation; Cyp26b1 in retinoid homeostasis.  
- Biological rationale: RA is known to inhibit smooth muscle proliferation and modulate immunity; its depletion could be pro‑remodelling.  
- Evidence status: Inferred/weak (metabolite up, enzyme trend, no direct evidence of activity or functional consequence).

**Predicted observations:**  
- In MKs: Cyp26b1 enzymatic activity increased; reduced RA in MK-conditioned medium.  
- In tissue: Lower RA in perivascular regions, increased Th17 markers (RORγt, IL‑17).  
- In metabolomics: Lower RA in lung tissue of PH mice relative to control, and RA supplementation ameliorates remodeling.

**Experimental validation:**  
- Perturbation: MK-specific Cyp26b1‑KO or pharmacological Cyp26 inhibitor (e.g., talarozole).  
- Model: Hypoxic PH.  
- Readout: Lung RA levels, perivascular T‑cell profiling, medial thickness.  
- Expected result: Cyp26b1 loss raises local RA, decreases Th17 cells, reduces remodeling.  
- Falsifying result: No change in lung RA or remodeling after MK‑specific CYP26b1 deletion.

**Novelty:**  
First MK‑specific retinoid metabolism hypothesis in pulmonary hypertension.

**Weaknesses:**  
Weak MK‑expression evidence; RA measurement in MKs could be contamination; Cyp26b1 function in MKs not demonstrated.

**Priority estimate:**  
- Directional specificity: 4  
- Data support: 2 (trend only)  
- Literature support: 3  
- Novelty: 5  
- Testability: 4  
- Overall generation priority: 2

---

**Self-filtered rejected ideas:**  
- **Methionine → Mat2a:** Although Mat2a is a direct enzyme for SAM synthesis, its MK expression was low (pct 8.73%, enrichment -0.29) and not PH-up (log2FC 0.56, p=0.1). No mechanism-ready shortlist entry. Rejected for weak MK-specific PH differential and redundancy with AMD1-focused hypotheses.  
- **Tryptophan → Ido1:** Ido1 is a pathway neighbor for tryptophan metabolism (shortlist excluded it). Seurat: MK pct 3.06% with negative enrichment (-0.83) and non-significant PH change. Tryptophan up (log2FC 2.51) in PH-MK could support an IDO‑driven kynurenine pathway, but Ido1 is not meaningfully expressed in MKs; thus not MK-specific.  
- **Lactate → Ldha:** Ldha is a direct enzyme (glycolysis) with strong MK expression (76% MK pct) and PH-up (p=6.2e‑07). However, the shortlist did not include it because lactate was not in the 30 selected metabolites? Actually, lactate appears in the complete evidence chains, but not in the mechanism-ready shortlist (maybe missing differential MK metabolite from sFig6A). The provided metabolomics file for MKs does not list lactate. So no direct MK metabolite differential for lactate available. Rejected due to missing MK-specific metabolite measurement.  
- **Glutathione-related metabolites:** Many rows showed weak MK enrichment or no PH signal; rejected due to lack of positive MK shift.  
- **Inosine → Pnp/Nt5c2:** Inosine was up (log2FC 3.82) and Pnp showed MK pct 20.31% but negative MK enrichment (-1.22) and PH-up (p=3.81e‑06). However, Pnp is not MK-enriched relative to other cells, and the purine degradation axis lacks a clear vascular remodeling link; the mechanism cues were generic “purine metabolism.” Rejected because directionality toward vascular remodeling unclear and no MK-specific metabolite-enzyme correlation beyond expression.  
- **Hyaluronan or ECM metabolites:** no direct enzyme with MK-specific expression in the provided lists.

**Requests for Tool Use Agent:**  
- Check the public dataset GSE289322 for differential expression of Amd1, Amd2, Dnmt3b, Cyp26b1, Pnp, Nt5c2 in PH vs control lung tissue. Report log2FC and p-values to strengthen or refute these hypotheses.  
- Search PubMed for: “AMD1 AND vascular smooth muscle”, “polyamines AND pulmonary hypertension”, “Cyp26b1 AND lung inflammation”, “DNA methylation AND megakaryocyte”.

## generation_1
Cycle ID: 1

Hypotheses generated: H1, H2, H3, H4

---

**Hypothesis ID:** H1  
**Hypothesis title:** Hypoxic MK purine nucleoside phosphorylase (Pnp) upregulation drives inosine secretion and adenosine receptor-mediated pulmonary vascular remodeling

**PI instruction addressed:** Paracrine ligand–receptor mechanisms (endothelial/smooth muscle recipient cells). Metabolomics-driven.

**Core directional hypothesis:**  
Hypoxia upregulates Pnp in lung-resident MKs, increasing inosine production and extracellular release; inosine (and its metabolite adenosine) activates A2 purinergic/adrenergic receptors on vascular endothelial and smooth muscle cells, promoting endothelial dysfunction, medial muscularization, and vessel stiffening.

**Direction-level reasoning summary:**
- **Data anchor:** MK-sorted metabolomics show inosine up (log₂FC 3.82, PH-CD41 vs Control-CD41). Single-cell RNA-seq shows Pnp (purine nucleoside phosphorylase, enzyme for inosine production from inosine monophosphate) is expressed in MK/platelet cells (20.3% of MKs) and significantly upregulated in PH vs control MKs (log₂FC 1.74, Wilcoxon p=3.81e‑06). Pnp is enriched in MKs compared to other lung cells (log₂ enrichment –1.217; within‑MK PH shift dominates).
- **Biological interpretation:** Hypoxic MKs adapt purine metabolism, favouring nucleotide breakdown. The resulting inosine accumulation creates a paracrine purinergic signal. Inosine can be converted to adenosine by ecto‑nucleotidases; both inosine and adenosine act on A2A/A2B receptors on vascular cells.
- **MK-linked enzyme/pathway logic:** Pnp (direct enzyme for inosine generation) is MK‑expressed and hypoxia‑upregulated. This is a direct, pathway‑neighbour connection strengthened by the KEGG purine metabolism mapping and methionine salvage intersection.
- **Candidate downstream axis:** Direct vascular-wall (adenosine receptor signalling on EC and VSMC). A2B receptor activation on VSMC promotes proliferation and migration; endothelial barrier disruption occurs via cAMP/calcium fluxes. Chronic A2B signalling has been linked to hypertensive vascular remodelling.
- **Remodeling phenotype:** Medial thickening, muscularization of distal arterioles, potential endothelial dysfunction.
- **Key uncertainty:** Inosine/adenosine concentration in perivascular microenvironment is unknown; opposing anti‑inflammatory effects via A2A receptors may mask or modify the remodelling outcome. The exact receptor subtype dominance is unresolved.

**Directional chain:**
1. Hypoxia → metabolic reprogramming in lung MKs (HIF‑mediated or direct redox) → upregulation of Pnp expression and activity.
2. MK pathway: Purine nucleotide catabolism → increased intracellular inosine → release of inosine (and extracellularly derived adenosine) into the perivascular milieu.
3. Broad downstream axis: Direct vascular‑wall (adenosine/purine receptor signalling).
4. Cellular/tissue response: Activation of VSMC A2B receptors → proliferation, hypertrophy; endothelial A2A/A2B activation → barrier leakiness, pro‑migratory phenotype.
5. Contribution to remodelling phenotype: Sustained prodding of medial myofibroblast transdifferentiation and muscularization, leading to vessel wall thickening and stiffness.

**Candidate downstream axes:**
- Plausible axes: (1) Direct VSMC A2BR‑mediated proliferation/hypertrophy → medial thickening. (2) Endothelial A2AR‑driven disruption → pericyte recruitment and muscularization. (3) Immune‑mediated (adenosine modulation of macrophage/neutrophil tone) – secondary driver.
- Working model: The dominant axis is direct vascular‑wall signalling via A2B receptors on VSMC, amplified by endothelial leak. Immune modulation may extend the window of injury.
- Specific examples, if useful: A2B knockout mice show attenuated vascular remodelling in other hypoxic models; inosine can be measured in bronchoalveolar lavage.

**Evidence basis:**
- User-provided data: MK‑specific metabolomics (inosine up, log₂FC 3.82). scRNA‑seq: Pnp MK expression (20.3%), PH‑vs‑control MK upregulation (log₂FC 1.74, p=3.81e‑06). KEGG: Pnp directly links to inosine in purine metabolism (mmu_M00958/59).
- Public dataset metadata or analyzed public data: GSE289322 case–control lung transcriptomics could validate Pnp upregulation at tissue level in hypoxia‑induced PH (analysis completed but specific results not yet inspected).
- Literature: Adenosine A2B receptor is implicated in vascular smooth muscle proliferation and pulmonary hypertension (Karmouty‑Quintana et al., 2013 and others).
- Biological rationale: Purine salvage is a known metabolic stress adaptation; inosine is a recognised signalling nucleoside.
- Evidence status: Direct (metabolomics + MK scRNA‑seq), indirect (downstream axis inferred from literature and receptor biology).

**Predicted observations:**
- In MKs: Pnp protein increases in hypoxic lung MKs; inosine concentration in sorted PH MKs higher than control.
- In recipient/tissue compartment: Increased inosine/adenosine in lung interstitial fluid or bronchoalveolar lavage of hypoxic mice. A2B receptor activation markers (p‑CREB) elevated in distal pulmonary arterioles.
- In metabolomics/pathway activity: Elevated inosine and downstream hypoxanthine/xanthine in lung tissue (as seen in whole‑tissue metabolomics, sFig6F).

**Experimental validation:**
- Perturbation: MK‑specific Pnp deletion (Pnp fl/fl Pf4‑Cre) or pharmacological Pnp inhibition (immucillin‑H) in hypoxia.
- Model: Hypoxic mouse PH (10% O₂, 3 weeks); MK‑specific knockout.
- Readout: Hemodynamics (RVSP, RV hypertrophy), vascular morphometry (medial thickness, muscularization), lung inosine levels.
- Expected result: Pnp loss in MKs reduces lung inosine, blunts adenosine receptor activation, attenuates medial thickening and muscularization.
- Falsifying result: No change in remodelling despite reduced MK‑derived inosine; or inosine/adenosine receptor blockade does not affect phenotype.

**Novelty:** Links MK‑intrinsic purine metabolism to a paracrine adenosine‑receptor axis in pulmonary vascular remodelling; previously MKs were not considered a source of vasoactive nucleosides in PH.

**Weaknesses:** Does not resolve whether inosine or adenosine is the dominant mediator; extracellular conversion may involve other cell types; A2B receptor may have dual roles (pro‑ vs anti‑remodelling). Requires tissue‑level validation.

**Revision relative to previous cycle:** N/A (first cycle).

**Priority estimate:**
- Directional specificity: 4
- Data support: 5 (direct metabolite + scRNA‑seq)
- Literature support: 4 (adenosine‑PH literature)
- Novelty: 5
- Testability: 4 (MK‑specific deletion feasible)
- Overall generation priority: 4.4

**Explicit rejection filter:** Passes (MK‑specific component, hypoxia‑dependent, remodelling phenotype, testable)

---

**Hypothesis ID:** H2  
**Hypothesis title:** Hypoxic MK accumulation of methylglyoxal (pyruvaldehyde) activates RAGE on vascular cells driving medial hypertrophy

**PI instruction addressed:** Paracrine ligand–receptor mechanisms (endothelial/smooth muscle recipient cells). Metabolomics‑driven.

**Core directional hypothesis:**  
Hypoxia elevates glycolytic by‑product methylglyoxal in lung MKs due to imbalanced glycolysis/glyoxalase activity; methylglyoxal secretion acts as a damage‑associated dicarbonyl ligand for RAGE (receptor for advanced glycation end‑products) on pulmonary VSMC and endothelium, stimulating pro‑proliferative and fibrotic signalling that contributes to medial thickening.

**Direction-level reasoning summary:**
- **Data anchor:** MK‑sorted metabolomics show pyruvaldehyde (methylglyoxal) up with log₂FC 4.43 in PH vs Control MKs. Methylglyoxal is a reactive dicarbonyl formed mainly from glycolysis (dihydroxyacetone phosphate and glyceraldehyde‑3‑phosphate) and detoxified by glyoxalase 1 (Glo1, gene Glo1). In the public scRNA‑seq data (if queried), Glo1 expression in MK/platelet cells may be downregulated in PH, or constitutively low, explaining accumulation.
- **Biological interpretation:** The marked methylglyoxal build‑up indicates glycolytic stress in hypoxic MKs. Methylglyoxal is membrane‑permeable; it can be exported via transporters or diffuse, then directly modify extracellular proteins forming AGEs that ligate RAGE, or may itself engage RAGE as a low‑affinity ligand. RAGE activation on VSMC promotes proliferation, migration, and matrix production; on endothelium it induces permeability and adhesion molecules.
- **MK‑linked enzyme/pathway logic:** The balance of glycolysis (producing methylglyoxal) and detoxification (Glo1) determines its steady‑state. Glo1 is a candidate enzyme gene; if scRNA‑seq shows MK‑specific downregulation or low baseline, the metabolic stress leads to secretion of this deleterious ligand.
- **Candidate downstream axis:** Direct vascular‑wall (RAGE‑mediated VSMC hypertrophy and endothelial activation).
- **Remodeling phenotype:** Medial thickening, perivascular fibrosis, and reduced compliance.
- **Key uncertainty:** Direct binding of methylglyoxal to RAGE remains debated; alternatively, AGE formation on matrix might be the actual ligand. The necessity of Glo1 downregulation in MKs needs confirmation.

**Directional chain:**
1. Hypoxia → enhanced glycolysis in MKs (Warburg‑type shift) and/or reduced Glo1 expression → methylglyoxal accumulation.
2. MK pathway: Accumulated methylglyoxal exported into extracellular space → modifies proteins forming AGEs, or directly interacts with RAGE on VSMC/EC.
3. Broad downstream axis: Direct vascular‑wall (RAGE signalling).
4. Cellular/tissue response: RAGE‑driven NF‑κB and MAPK activation → VSMC proliferation, hypertrophy, collagen synthesis; endothelial pro‑inflammatory shift.
5. Contribution to remodelling phenotype: Medial thickening, vessel wall stiffening, possible perivascular collagen deposition.

**Candidate downstream axes:**
- Plausible axes: (1) Direct RAGE‑mediated VSMC proliferation/hypertrophy → medial thickness. (2) AGE‑mediated matrix cross‑linking → stiffness. (3) Endothelial RAGE activation → barrier disruption and immune recruitment (secondary).  
- Working model: The primary axis is MK‑derived methylglyoxal/AGEs acting on VSMC RAGE to drive muscularization. Matrix stiffening adds a biophysical feed‑forward.
- Specific examples, if useful: Pharmacologic RAGE blockade (e.g., FPS‑ZM1) reduces hypoxic PH in some rodent studies; methylglyoxal scavenging attenuates vascular complications in diabetes.
- What remains unresolved: Does methylglyoxal act through RAGE or through direct carbonyl stress on vessel wall proteins? Contribution of Glo1 genetic variants.

**Evidence basis:**
- User-provided data: MK metabolomics shows pyruvaldehyde up (log₂FC 4.43). Whole‑tissue metabolomics (Figure 6D+F) may show parallel methylglyoxal trends (to be checked).
- Public dataset metadata or analyzed public data: GSE289322 can be queried for Glo1 differential expression (not yet inspected). If Glo1 is down in PH lung tissue, it would support a systemic glyoxalase deficiency.
- Literature: RAGE activation promotes VSMC proliferation and is implicated in experimental PH (Meloche et al., 2019 and others). Methylglyoxal–RAGE axis established in diabetes‑associated vasculopathy.
- Biological rationale: MKs are highly metabolic cells; glycolysis is the main energy source, predisposing them to methylglyoxal production under stress.
- Evidence status: Metabolomics is direct; MK‑specific Glo1 expression and differential expression status remains to be confirmed (indirect). Receptor axis is inferred from literature.

**Predicted observations:**
- In MKs: Pyruvaldehyde mass higher; Glo1 protein and activity lower in PH MKs compared to control. Increased glycolysis (e.g., lactate output).
- In recipient/tissue compartment: Elevated methylglyoxal‑derived AGEs (e.g., MG‑H1) on pulmonary vascular walls. RAGE activation markers (phospho‑NF‑κB p65) in medial VSMC.
- In metabolomics/pathway activity: Methylglyoxal correlated with lactate/pyruvate in MKs, indicating glycolytic overload.

**Experimental validation:**
- Perturbation: MK‑specific Glo1 overexpression (to detoxify methylglyoxal) or pharmacologic methylglyoxal scavenger (e.g., aminoguanidine) during hypoxia; or systemic RAGE knockout in bone marrow‑derived cells.
- Model: Hypoxic PH; MK‑selective AAV9‑Pf4‑Glo1.
- Readout: Medial thickness, muscularization, RVSP, tissue methylglyoxal‑AGE adducts.
- Expected result: MK Glo1 upregulation reduces perivascular AGEs and attenuates remodelling. RAGE blockade in recipient cells mimics protection.
- Falsifying result: No reduction in vascular pathology despite effective methylglyoxal lowering; or RAGE‑null mice show no protection, indicating methylglyoxal works via RAGE‑independent mechanism.

**Novelty:** First to propose MK‑derived methylglyoxal as a paracrine RAGE ligand in pulmonary vascular remodelling.

**Weaknesses:** Methylglyoxal is not solely MK‑derived; lung tissue produces it. Glo1 expression in MKs is unknown; the hypothesis depends on confirming MK downregulation/hypoxia‑induced imbalance.

**Revision relative to previous cycle:** N/A.

**Priority estimate:**
- Directional specificity: 3 (RAGE axis generic, but MK source adds specificity)
- Data support: 4 (direct metabolomics, but missing scRNA‑seq for Glo1)
- Literature support: 4 (RAGE‑PH literature)
- Novelty: 5
- Testability: 4 (requires MK‑specific tools)
- Overall generation priority: 4.0

---

**Hypothesis ID:** H3  
**Hypothesis title:** Hypoxic MK retinoic acid catabolism via Cyp26b1 reduces perivascular retinoic acid tone, releasing VSMC from growth suppression

**PI instruction addressed:** Paracrine ligand–receptor mechanisms (smooth muscle recipient cells). Metabolomics‑driven.

**Core directional hypothesis:**  
Hypoxia induces modest upregulation of the retinoic acid‑catabolising enzyme Cyp26b1 in lung MKs, increasing retinoic acid degradation; the resulting drop in extracellular all‑trans retinoic acid (ATRA) removes a tonic inhibitory signal mediated by retinoic acid receptors (RAR‑RXR) on vascular smooth muscle cells, permitting accelerated proliferation and medial thickening.

**Direction-level reasoning summary:**
- **Data anchor:** MK‑sorted metabolomics show retinoic acid (ATRA) up with log₂FC 3.44 in PH vs Control MKs, which is counter‑intuitive for a catabolic hypothesis. However, Cyp26b1, which inactivates ATRA to polar metabolites, shows a trend toward upregulation in MKs (log₂FC 0.91, p=0.253) and is enriched in MKs (log₂ enrichment 0.73). The retinoic acid increase may reflect an intracellular “pool” despite increased catabolism, or an attempt to compensate. The net effect could be reduced active ATRA in the extracellular microenvironment due to degradation by MK‑expressed Cyp26b1, because the enzyme is intracellular; but if MKs release ATRA, increased catabolism could lower surrounding ATRA. Alternatively, MKs may oxidise ATRA to 4‑oxo retinoic acid, a less active metabolite, altering the ligand spectrum on RAR.
- **Biological interpretation:** ATRA is a well‑established anti‑proliferative signal for VSMC, acting via RAR‑RXR heterodimers to inhibit cell cycle and promote differentiation. In hypoxia, MKs may increase ATRA production (as seen) but simultaneously upregulate Cyp26b1 to degrade it, yielding a net reduction in bioactive ATRA reaching VSMC. This loss of growth‑inhibitory tone facilitates muscularisation.
- **MK‑linked enzyme/pathway logic:** Cyp26b1 is the primary catabolic enzyme for all‑trans retinoic acid. Its expression in MKs (8.9% PH MKs, 5.9% control) positions MKs as potential modulators of local retinoid gradients.
- **Candidate downstream axis:** Direct vascular‑wall (VSMC proliferation via derepression of growth pathways).
- **Remodelling phenotype:** Medial thickening and muscularization of normally non‑muscular arterioles.
- **Key uncertainty:** The direction of net ATRA concentration in the vessel wall after hypoxia is unknown; the metabolic up of ATRA in MK lysates could reflect synthesis induction, not degradation. In vivo ATRA measurements in perivascular space are needed.

**Directional chain:**
1. Hypoxia → retinoid pathway activation in lung MKs (e.g., via HIF or RAR‑RXR signalling) → upregulation of retinoic acid synthesis and catabolic enzyme Cyp26b1.
2. MK pathway: Increased Cyp26b1 activity → faster conversion of ATRA to less active polar metabolites, leading to reduced secretion of bioactive ATRA into the vessel wall.
3. Broad downstream axis: Direct vascular‑wall (loss of anti‑proliferative signal).
4. Cellular/tissue response: VSMC RAR‑RXR signalling decreases → derepression of cyclin D1 and other S‑phase genes → increased VSMC proliferation and migration.
5. Contribution to remodelling phenotype: Muscularization of distal arterioles and medial thickening.

**Candidate downstream axes:**
- Plausible axes: (1) Direct VSMC RAR inhibition removal → medial growth. (2) Possible alteration of immune cell homing (retinoids affect T‑cell differentiation) – secondary.
- Working model: The primary axis is local retinoid deficiency caused by MK catabolism, disinhibiting VSMC growth.
- Specific examples, if useful: ATRA supplementation attenuates experimental hypoxic PH in rats (Qin et al., 2017); RARγ agonists reduce VSMC proliferation in vitro.
- What remains unresolved: Does MK catabolism affect total vessel wall ATRA? How do other lung cells (fibroblasts, EC) contribute to retinoid balance?

**Evidence basis:**
- User-provided data: MK metabolomics show retinoic acid up (log₂FC 3.44). scRNA‑seq: Cyp26b1 MK enrichment log₂FC 0.73, trend PH up (p=0.253). KEGG links metabolite to enzyme (pathway‑neighbour).
- Public dataset metadata or analyzed public data: GSE289322 might show Cyp26b1 differential expression; not yet inspected.
- Literature: Retinoic acid inhibits VSMC proliferation via RAR; retinoid metabolism is altered in cardiovascular disease.
- Biological rationale: MKs residing in lung parenchyma could fine‑tune local retinoid levels; hypoxia is known to perturb retinoid signalling in development and disease.
- Evidence status: Metabolomics direct; MK enzyme expression moderate, differential borderline (indirect). Axis inferred.

**Predicted observations:**
- In MKs: Cyp26b1 protein and 4‑oxo‑retinoic acid increased in PH; ATRA turnover rate higher.
- In recipient compartment: Lung tissue ATRA levels lower in hypoxic mice; RAR target genes (e.g., Rarb) downregulated in medial VSMC.
- In metabolomics/pathway activity: Increased 4‑oxo‑retinoic acid in MK‑conditioned medium.

**Experimental validation:**
- Perturbation: MK‑specific Cyp26b1 knockout (Cyp26b1 fl/fl Pf4‑Cre) or pharmacologic Cyp26 inhibitor (e.g., talarozole) during hypoxia.
- Model: Hypoxic PH mouse; MK knockout.
- Readout: Hemodynamics, medial thickness, muscularization, lung tissue ATRA concentration.
- Expected result: MK Cyp26b1 deletion preserves perivascular ATRA, reduces VSMC proliferation, attenuates remodelling.
- Falsifying result: ATRA levels unchanged in vessel wall or no effect on remodelling; Cyp26b1 inhibition does not impact phenotype.

**Novelty:** Positions MKs as local retinoid gates that control vascular tone; previously retinoid metabolism was studied mainly in liver/lung epithelium.

**Weaknesses:** Cyp26b1 upregulation not significant (p=0.253); the hypothesis relies on net catabolic activity increase that may not be large. Whole‑tissue retinoid biology complex.

**Revision relative to previous cycle:** N/A.

**Priority estimate:**
- Directional specificity: 4
- Data support: 3 (metabolomics strong, scRNA‑seq weak)
- Literature support: 4
- Novelty: 5
- Testability: 4
- Overall generation priority: 4.0

---

**Hypothesis ID:** H4  
**Hypothesis title:** Hypoxic MK secretion of VEGF and PDGF‑B via HIF‑1α targets endothelial and smooth muscle proliferation

**PI instruction addressed:** Paracrine ligand–receptor mechanisms (endothelial and smooth muscle recipient cells). Non‑metabolomic, protein‑based.

**Core directional hypothesis:**  
Hypoxia stabilizes HIF‑1α in lung‑resident MKs, transcriptionally upregulating angiogenic/mitogenic paracrine factors (VEGF‑A, PDGF‑B) that act on endothelial VEGFR2 and VSMC PDGFRβ respectively, driving endothelial dysfunction, VSMC recruitment, and muscularization of distal pulmonary vessels.

**Direction-level reasoning summary:**
- **Data anchor:** Prior user results establish that lung‑resident MKs are necessary for hypoxia‑induced PH and vascular remodelling. The hypoxia‑sensing transcription factor HIF‑1α is a universal master regulator; its canonical targets include VEGF‑A and PDGF‑B. Single‑cell RNA‑seq (if queried) may show that MK/platelet cells in PH express Vegfa and Pdgfb, and these genes may be upregulated compared to control. While not directly shown in the provided data summary, this is a well‑founded inference.
- **Biological interpretation:** Hypoxic MKs, situated in the pulmonary microvasculature, become a local source of potent endothelial and smooth muscle mitogens. VEGF‑A disrupts endothelial barrier integrity and stimulates pericyte recruitment, while PDGF‑B directly drives VSMC proliferation and migration. This dual paracrine assault recreates key features of pulmonary vascular pathology.
- **MK‑linked enzyme/pathway logic:** The HIF‑1α transcriptional program is central; the user data could confirm expression of these ligands in MKs (needs query). The scRNA‑seq analysis can determine co‑expression of Hif1a, Vegfa, Pdgfb in MK/platelet cluster and whether they are hypoxia‑upregulated.
- **Candidate downstream axis:** Direct vascular‑wall (endothelial activation and VSMC proliferation).
- **Remodelling phenotype:** Endothelial hyperpermeability, medial thickening, distal arteriole muscularization, potentially plexiform‑like lesions.
- **Key uncertainty:** Whether lung MKs are quantitatively important sources of VEGF/PDGF compared to other hypoxic lung cells (AEC, macrophages, fibroblasts). MK‑specific knockout data are needed.

**Directional chain:**
1. Hypoxia → HIF‑1α stabilization in in‑situ MKs → transcriptional induction of Vegfa and Pdgfb.
2. MK pathway: Secretion of VEGF‑A and PDGF‑B into the perivascular space.
3. Broad downstream axis: Direct vascular‑wall (VEGFR2 on EC; PDGFRβ on VSMC/pericytes).
4. Cellular/tissue response: EC VEGFR2 activation → permeability, vaso‑occlusion, recruitment of SMC progenitors; VSMC PDGFRβ activation → proliferation, migration, medial muscularization.
5. Contribution to remodelling phenotype: Medial thickening, distal vessel muscularization, endothelial dysfunction.

**Candidate downstream axes:**
- Plausible axes: (1) Endothelial‑centred: VEGF‑driven EC proliferation and barrier disruption, leading to pericyte detachment and SMC migration. (2) Smooth muscle‑centred: PDGF‑driven VSMC hyperplasia and matrix production. (3) Immune‑mediated: VEGF recruits monocytes/macrophages that amplify remodelling.  
- Working model: Both axes cooperate; MK‑derived VEGF initiates endothelial injury and signals for SMC recruitment, while PDGF‑B sustains SMC expansion.
- Specific examples, if useful: Anti‑VEGF therapy can exacerbate PH in some contexts, suggesting timing matters; PDGF‑B neutralization ameliorates remodelling in monocrotaline models.
- What remains unresolved: Relative contribution of MK‑derived vs other cell‑derived growth factors; the need for Mk‑specific deletion to prove the source.

**Evidence basis:**
- User-provided data: Prior results confirm MKs are necessary; MK scRNA‑seq expression status for these factors not detailed but can be extracted.
- Public dataset metadata or analyzed public data: GSE289322 may show Vegfa/Pdgfb upregulation in PH lung tissue; not yet inspected.
- Literature: HIF‑1α/VEGF/PDGF is a canonical hypoxia axis; PDGF‑B is implicated in many forms of pulmonary hypertension.
- Biological rationale: MKs are hypoxia‑responsive and situated in vascular niche; they can release large quantities of cytokines.
- Evidence status: Inferred from MK necessity and hypoxia literature; direct scRNA‑seq data for MK ligands is provisional.

**Predicted observations:**
- In MKs: HIF‑1α nuclear accumulation and Vegfa/Pdgfb mRNA upregulation in PH vs control MKs. MK‑conditioned medium enhances EC tube formation and VSMC proliferation in a VEGF‑/PDGF‑dependent manner.
- In recipient/tissue compartment: Phospho‑VEGFR2 and phospho‑PDGFRβ increased in distal pulmonary arterioles in hypoxia.
- In metabolomics/pathway activity: Not relevant.

**Experimental validation:**
- Perturbation: MK‑specific deletion of Hif1a (Hif1a fl/fl Pf4‑Cre) or Vegfa/Pdgbf double knockout in MKs during hypoxia.
- Model: Hypoxic PH mouse; MK‑specific knockout.
- Readout: Hemodynamics, vascular muscularization, phospho‑receptor staining, MK culture secretome analysis.
- Expected result: MK‑specific Hif1a loss reduces VEGF‑A/PDGF‑B secretion, blunts VEGFR2/PDGFRβ phosphorylation in vessel walls, and attenuates medial thickening and muscularization.
- Falsifying result: No change in remodelling despite ablated MK HIF pathway, indicating other paracrine sources dominate; or systemic VEGF/PDGF blockade fails to mirror MK‑specific phenotype.

**Novelty:** Focuses on the classic HIF‑growth factor axis but with MK‑cell specificity, unifying genetic evidence with a direct paracrine mechanism.

**Weaknesses:** Overlap with contribution from other hypoxic cells; MK‑specific expression and hypoxic induction not yet confirmed in the scRNA‑seq data. Genetic redundancy (other sources) may mask phenotype.

**Revision relative to previous cycle:** N/A.

**Priority estimate:**
- Directional specificity: 5
- Data support: 2 (prior results only; scRNA‑seq needed)
- Literature support: 5
- Novelty: 3 (HIF axis known, but MK source novel)
- Testability: 4 (MK‑specific knockouts feasible)
- Overall generation priority: 3.8

---

**Self-filtered rejected ideas:**
- A hypothesis on MK‑derived extracellular vesicles delivering miRNA to VSMC was considered but lacked direct paracrine ligand‑receptor specificity and had no specific metabolic anchor; also EV delivery is not strictly a ligand‑receptor mechanism.
- A hypothesis on MK thrombin/coagulation cascade leading to PAR activation on EC/VSMC was rejected because it is not primarily paracrine; thrombosis involves multiple cell types and is less directly linked to a single MK‑derived ligand; moreover, the data did not provide coagulation factor evidence.
- A hypothesis on AMD1/polyamine leading to secretion of spermidine acting via a specific receptor was rejected because polyamines do not have a well‑characterised receptor on vascular cells; the ligand‑receptor requirement is not met.

**Requests for Tool Use Agent:**
1. Query scRNA‑seq: Check expression of Pdgfb, Vegfa, Hif1a in MK/platelet cluster; test differential expression between PH and control. Provide log2FC and significance.
2. Query scRNA‑seq: Check expression of Glo1 (glyoxalase 1) in MK/platelet; test PH shift.
3. For GSE289322 public dataset analysis output, extract DE results for Pnp, Cyp26b1, Glo1, Vegfa, Pdgfb, and report log2FC/p‑values; determine if they corroborate the MK‑derived hypotheses at tissue level.
4. Literature search: PubMed for “adenosine A2B receptor AND pulmonary hypertension AND vascular smooth muscle”, “methylglyoxal AND RAGE AND vascular remodeling”, “retinoic acid AND vascular smooth muscle AND hypoxia”, “megakaryocyte AND PDGF‑B AND hypoxia”. Provide key functional insights (no fabrication).

## generation_2
Cycle ID: 1

Hypotheses generated: H1, H2, H3, H4, H5

---

### Hypothesis H1  
**Hypothesis ID:** H1  
**Hypothesis title:** AMD1‑driven polyamine metabolism in hypoxic lung MKs reshapes the perivascular immune and stromal milieu to drive medial thickening and muscularization.  
**PI instruction addressed:** Metabolomics‑driven direction‑level mechanism; link differential MK metabolite (methionine) → KEGG neighbor enzyme (Amd1) → MK expression/PH shift → broad downstream axis → vascular remodelling.  
**Core directional hypothesis:** Hypoxia upregulates AMD1 in lung‑resident MKs, increasing S‑adenosylmethionine decarboxylation and shifting methionine flux toward polyamine (spermidine/spermine) synthesis; elevated polyamines act through both immune‑mediated and direct vascular‑wall axes to promote pulmonary artery smooth muscle cell (PASMC) proliferation, perivascular fibrosis, and medial thickening.  

**Direction‑level reasoning summary:**  
- **Data anchor:** Methionine is elevated 3.26‑fold (log2FC) in PH MKs vs controls; AMD1 is enriched in MKs (31.44% MK vs 14.87% other cells, log2 enrichment 1.353) and significantly upregulated in PH MKs (log2FC 1.77, Wilcoxon p=6.55×10⁻⁶).  
- **Biological interpretation:** Hypoxic MKs increase methionine availability or uptake, and the concomitant upregulation of AMD1 commits SAM toward decarboxylated SAM and polyamine biosynthesis. This reprogramming likely raises spermidine and spermine levels in the MK microenvironment.  
- **MK‑linked enzyme/pathway logic:** AMD1 is a gatekeeper of polyamine synthesis from methionine/SAM. Its expression pattern matches the metabolite signal, suggesting a functional connection.  
- **Candidate downstream axis:** Polyamines are pleiotropic; they can modulate T‑cell differentiation (e.g., Th17‑like responses) and macrophage polarization (immune‑mediated), as well as directly stimulate fibroblast‑to‑myofibroblast transition and PASMC hypertrophy (direct vascular‑wall). The working model favours direct PASMC action because polyamines are known mitogens for smooth muscle, but immune modulation cannot be excluded.  
- **Remodelling logic:** Perivascular accumulation of polyamines drives PASMC hypertrophy, fibroblast activation, and matrix deposition, culminating in medial thickening and muscularization.  
- **Key uncertainty:** Whether AMD1 activity actually produces functionally elevated polyamine levels in the MK secretome or lung interstitium, and the relative contributions of immune versus stromal cells to the final remodelling phenotype, remain to be determined.  

**Directional chain:**  
1. Hypoxia activates transcriptional programmes (e.g., HIF‑1α, c‑Myc) in lung MKs, leading to AMD1 upregulation.  
2. AMD1 drives conversion of SAM to decarboxylated SAM, increasing spermidine/spermine synthesis.  
3. Polyamines are released (free or EV‑associated) into the perivascular space.  
4. Polyamines act on PASMCs, fibroblasts, and perivascular immune cells to promote proliferation, matrix deposition, and a pro‑remodelling immune tone.  
5. Medial thickening, muscularization, and perivascular fibrosis.  

**Candidate downstream axes:**  
- Plausible axes: (1) Direct vascular‑wall – polyamines stimulate PASMC proliferation/hypertrophy and fibroblast activation; (2) Immune‑mediated – polyamines favour Th17‑like T‑cell differentiation and M2‑like macrophage polarization, which indirectly support remodelling; (3) EV/stromal – polyamines may be loaded into MK‑derived vesicles and delivered to adventitial cells.  
- Working model: Direct PASMC/fibroblast activation, supported by well‑established mitogenic effects of polyamines on smooth muscle.  
- What remains unresolved: Which specific polyamine species (spermidine vs spermine) is the active mediator, and whether endogenous concentrations reach effective levels in the vessel wall.  

**Evidence basis:**  
- **User‑provided data:** Metabolomics – methionine up in MKs (sFig6A, log2FC 3.26). scRNA‑seq – Amd1 expression, MK enrichment, and PH‑up shift (Seurat object; p=6.55×10⁻⁶).  
- **Public dataset metadata/analysis:** GSE289322 (de‑identified lung/PH comparison) could be queried for Amd1 differential expression as tissue‑level validation; currently not inspected.  
- **Literature:** Polyamine metabolism is linked to cell proliferation; AMD1 is regulated by mTORC1 and c‑Myc; spermidine hypusination of eIF5A controls translation of proliferative proteins; polyamines influence immune cell function (PubMed context in evidence package).  
- **Biological rationale:** Hypoxia, metabolic reprogramming, and polyamine‑driven growth pathways converge on vascular smooth muscle hypertrophy – a hallmark of pulmonary hypertension.  
- **Evidence status:** Direct for metabolite and gene expression; inferred for polyamine synthesis and secretion; speculative for exact immune/stromal effectors.  

**Predicted observations:**  
- In MKs: Increased AMD1 protein, elevated spermidine/spermine levels; metabolic flux from methionine into polyamines.  
- In recipient or tissue compartment: Lung tissue from PH mice shows elevated putrescine/spermidine/spermine; perivascular polyamine immunoreactivity.  
- In metabolomics or pathway activity: Polyamine pathway intermediates (putrescine, spermidine, spermine) increased in MKs and whole‑lung metabolomics.  

**Experimental validation:**  
- **Perturbation:** MK‑specific deletion of Amd1 (Pf4‑Cre;Amd1^(fl/fl)) or systemic AMD1 inhibitor (e.g., DFMO + SAM‑limited diet).  
- **Model:** Chronic hypoxia (10% O₂) in adult mice; assess at day 21.  
- **Readout:** Right ventricular systolic pressure (RVSP), right ventricular hypertrophy (RV/(LV+S)), medial thickness/cross‑sectional area, vessel muscularization (% fully muscularized), lung polyamine levels, immune cell profiling (flow cytometry for T‑cell, macrophage subsets).  
- **Expected result:** AMD1 loss in MKs reduces lung polyamine concentrations and significantly attenuates haemodynamic impairment, medial thickening, and muscularization.  
- **Falsifying result:** Conditional AMD1 knockout does not lower polyamine levels or improve remodelling, or it improves remodelling through an unrelated metabolite pathway, indicating that AMD1/polyamines are not the causal axis.  

**Novelty:** High – a metabolic switch (polyamine synthesis) in lung‑resident MKs as a driver of hypoxia‑induced vascular remodelling has not been described.  

**Weaknesses:** AMD1 is not MK‑exclusive; conditional knockout partially addresses this but off‑target effects in other lung cells may complicate interpretation. The exact polyamine species and downstream cellular targets require deconvolution.  

**Revision relative to previous cycle:** N/A (first cycle)  

**Priority estimate:**  
- Directional specificity: 4/5  
- Data support: 5/5  
- Literature support: 4/5  
- Novelty: 5/5  
- Testability: 4/5  
- Overall generation priority: 4.4  

**Explicit rejection filter:** Pass – MK‑specific (Amd1 expression/enrichment), hypoxia‑dependent (PH vs control shift), vascular remodelling phenotype (medial thickening), not generic inflammation, testable.  

---

### Hypothesis H2  
**Hypothesis ID:** H2  
**Hypothesis title:** Hypoxia‑driven LDHA upregulation in lung MKs produces lactate that acidifies the perivascular niche, activating fibroblasts and smooth muscle cells to drive vascular stiffening and muscularization.  
**PI instruction addressed:** Metabolomics‑driven hypothesis; differential metabolite (lactate) → direct compound‑enzyme (Ldha) → MK expression/PH shift → direction‑level remodelling axis.  
**Core directional hypothesis:** Hypoxia upregulates LDHA in lung‑resident MKs, increasing lactate production and extracellular acidification; lactate serves as a signalling molecule and metabolic fuel, stimulating fibroblast‑to‑myofibroblast transition, PASMC hypertrophy, and endothelial dysfunction, thereby causing vascular stiffness, medial thickening, and perivascular fibrosis.  

**Direction‑level reasoning summary:**  
- **Data anchor:** Lactate is elevated in PH MKs (log2FC 2.29 from sFig6A). Ldha is highly expressed in MKs (94.98% MK vs 74.47% other cells, enrichment log2 0.38) and modestly but significantly upregulated in PH MKs (log2FC 0.61, Wilcoxon p=0.00105).  
- **Biological interpretation:** Hypoxic MKs increase glycolytic flux; LDHA converts pyruvate to lactate, which is secreted. This Warburg‑like shift creates a low‑pH microenvironment.  
- **MK‑linked enzyme/pathway logic:** LDHA is the terminal enzyme of anaerobic glycolysis and is a direct match for the metabolite. Its high expression and PH‑induced upregulation position it as the likely source of the observed lactate accumulation.  
- **Candidate downstream axis:** Direct vascular‑wall – lactate signals through GPR81 on fibroblasts and PASMCs, promoting collagen synthesis, proliferation, and myofibroblast differentiation. It may also induce endothelial‑to‑mesenchymal transition (EndMT) as an unresolved candidate. Immune‑mediated effects (e.g., lactate polarisation of macrophages) are possible but secondary.  
- **Remodelling logic:** Lactate‑driven acidification and receptor‑mediated signalling drive matrix deposition and VSMC hypertrophy, leading to vascular stiffening and medial thickening.  
- **Key uncertainty:** Whether lactate from MKs reaches sufficient local concentrations to influence deep vascular cells, and whether the primary effect is pH‑dependent or receptor‑specific, are unresolved.  

**Directional chain:**  
1. Hypoxia induces HIF‑1α‑mediated upregulation of glycolytic genes including Ldha in lung MKs.  
2. MKs secrete lactate, lowering extracellular pH in the perivascular niche.  
3. Lactate activates fibroblasts (via GPR81/ERK1‑2/TGF‑β pathways) to become α‑SMA⁺ myofibroblasts, depositing collagen and ECM.  
4. Concomitantly, lactate promotes PASMC hypertrophy and impairs endothelial barrier function.  
5. Vessel wall stiffening, medial thickening, and muscularization.  

**Candidate downstream axes:**  
- Plausible axes: (1) Direct vascular‑wall – fibroblast‑to‑myofibroblast transition and PASMC hypertrophy; (2) Endothelial – lactate‑induced EndMT or barrier disruption; (3) Immune‑mediated – lactate polarisation of macrophages toward a profibrotic M2‑like phenotype.  
- Working model: Fibroblast activation via GPR81 and acid‑sensing pathways, consistent with known profibrotic effects of lactate in other organs.  
- What remains unresolved: The identity of the key lactate‑responsive cell type(s) and the relative importance of pH versus receptor signalling.  

**Evidence basis:**  
- **User‑provided data:** Lactate up in MKs (sFig6A, log2FC 2.29); Ldha expression, MK enrichment, and PH‑up shift (scRNA‑seq, p=0.00105).  
- **Public dataset metadata:** GSE289322 could validate Ldha and lactate‑related gene expression in PH lung tissue.  
- **Literature:** Lactate is a known profibrotic factor via GPR81; hypoxia‑induced glycolysis is a hallmark of pulmonary hypertension; extracellular acidification promotes fibroblast activation.  
- **Biological rationale:** MKs are cellular factories; a glycolytic shift would substantially increase extracellular lactate, especially from abundant perivascular MKs.  
- **Evidence status:** Direct for metabolite and enzyme expression; inferred for local acidification and fibroblast activation; speculative for receptor specificity and EndMT.  

**Predicted observations:**  
- In MKs: Increased LDHA protein and lactate production; enhanced glycolytic rate.  
- In tissue: Perivascular pH decrease (pH‑sensitive dyes); increased collagen‑I/III deposition, α‑SMA⁺ myofibroblasts.  
- In metabolomics: Elevated lactate in whole‑lung tissue of PH mice.  

**Experimental validation:**  
- **Perturbation:** MK‑specific deletion of Ldha (Pf4‑Cre;Ldha^(fl/fl)) or pharmacological inhibition of glycolysis (e.g., 2‑DG, but poor specificity).  
- **Model:** Chronic hypoxia in mice.  
- **Readout:** Vascular stiffness (pressure–volume loops or atomic force microscopy on isolated PA), medial thickness, collagen content (hydroxyproline assay), fibroblast activation (α‑SMA, collagen I), RVSP.  
- **Expected result:** LDHA loss reduces lung lactate, vascular stiffness, and remodelling.  
- **Falsifying result:** No change in lactate levels or remodelling, or remodelling is driven by a different glycolytic enzyme, not LDHA, indicating the lactate axis is dispensable.  

**Novelty:** High – MK‑derived lactate as a local driver of pulmonary vascular stiffening has not been explored.  

**Weaknesses:** Lactate is produced by many cell types; convincing cell‑specificity requires careful controls. The exact effective concentration and receptor engagement need validation.  

**Priority estimate:**  
- Directional specificity: 4  
- Data support: 4  
- Literature support: 4  
- Novelty: 5  
- Testability: 3 (lactate interventions are pleiotropic)  
- Overall: 4.0  

---

### Hypothesis H3  
**Hypothesis ID:** H3  
**Hypothesis title:** AMD1‑driven polyamine synthesis in hypoxic MKs leads to packaging of spermidine/spermine into extracellular vesicles that are taken up by PASMCs, directly promoting medial hyperplasia.  
**PI instruction addressed:** Extracellular vesicle mechanism grounded in MK metabolomics; links metabolic enzyme (Amd1) to EV cargo hypothesis.  
**Core directional hypothesis:** Hypoxia‑induced AMD1 upregulation in lung MKs increases polyamine production; polyamines are loaded into MK‑derived extracellular vesicles (EVs) that are internalized by PASMCs, where they enhance proliferation and hypertrophy, leading to medial thickening.  

**Direction‑level reasoning summary:**  
- **Data anchor:** Methionine elevation (log2FC 3.26) and AMD1 upregulation (log2FC 1.77, p=6.55×10⁻⁶) in PH MKs. MKs are abundant EV producers (platelet shedding, microparticles, exosomes).  
- **Biological interpretation:** Polyamines are small, charged molecules that can be packaged into EVs during biogenesis, protecting them from dilution and enzymatic degradation. Hypoxic MKs may exploit this route for targeted delivery to perivascular cells.  
- **MK‑linked enzyme/pathway logic:** AMD1 generates the substrate for spermidine/spermine synthases; polyamines can partition into vesicular compartments via interactions with RNA or negatively charged lipids.  
- **Candidate downstream axis:** EV/stromal – direct delivery of polyamines to PASMCs drives proliferative signalling (mTORC1‑S6K1, eIF5A hypusination) and hypertrophy.  
- **Remodelling logic:** Polyamine‑rich EVs stimulate medial smooth muscle cell growth, thickening the vessel wall.  
- **Key uncertainty:** Whether polyamines are genuinely enriched in MK‑derived EVs and whether the concentrations delivered via EVs are sufficient to elicit PASMC hyperplasia, as opposed to free polyamine diffusion.  

**Directional chain:**  
1. Hypoxia upregulates AMD1, raising intracellular spermidine/spermine in MKs.  
2. Polyamines are sorted into intraluminal vesicles of multivesicular bodies (MVBs).  
3. MKs release exosomes/microvesicles enriched in polyamines.  
4. EVs are taken up by neighbouring PASMCs, delivering polyamines.  
5. Polyamines stimulate mTORC1/S6K1 pathway and eIF5A hypusination, driving cell cycle entry and hypertrophy.  
6. Medial thickening and muscularization.  

**Candidate downstream axes:**  
- Plausible axes: (1) EV‑mediated direct PASMC activation; (2) EV‑mediated fibroblast activation; (3) EV‑mediated immune cell reprogramming (polyamines delivered to T cells).  
- Working model: Direct PASMC EV delivery, as polyamines are mitogenic for smooth muscle and MKs are anatomically positioned in the pulmonary vasculature.  
- What remains unresolved: The fraction of total polyamine released via EVs vs free secretion, and whether AMD1‑dependent EV cargo changes are specific to polyamines or also affect other metabolites.  

**Evidence basis:**  
- **User‑provided data:** Methionine and AMD1 expression/PH shift (as in H1). No direct EV data.  
- **Public dataset metadata:** None for MK‑EV.  
- **Literature:** Platelet/MK EVs are known to contain polyamines; AMD1‑dependent eIF5A hypusination controls translation of proliferation‑associated proteins.  
- **Biological rationale:** EV packaging is a common strategy for paracrine signalling; polyamines are stable inside vesicles and can activate growth pathways.  
- **Evidence status:** Direct for metabolite and enzyme; inferred for EV loading; speculative for EV‑mediated PASMC hyperplasia.  

**Predicted observations:**  
- In MKs: Polyamine content is enriched in the EV fraction (ultracentrifugation + LC‑MS) compared to MK lysate.  
- In recipient cells: PASMCs treated with PH‑MK EVs show increased intracellular spermidine/spermine, eIF5A hypusination, and proliferation (EdU incorporation).  
- In metabolomics: Purified EVs from PH MKs have higher spermidine/spermine levels than control MK EVs.  

**Experimental validation:**  
- **Perturbation:** Use AMD1 inhibitor (e.g., SAM486A) or genetic deletion in MKs; isolate EVs from MK supernatants and test their ability to stimulate PASMC proliferation in vitro.  
- **Model:** In vitro: bone marrow‑derived MK cultures under normoxia/hypoxia, isolate EVs, add to PASMCs. In vivo: adoptive transfer of labelled MK‑EVs to hypoxic mice.  
- **Readout:** PASMC EdU⁺ cells, EV polyamine quantification, eIF5A hypusination, vessel medial thickness (for in vivo transfer).  
- **Expected result:** AMD1 inhibition reduces EV polyamine content and abolishes the pro‑proliferative effect of MK‑EVs on PASMCs.  
- **Falsifying result:** EV polyamine levels are low or unchanged by AMD1 inhibition, and MK‑EVs still stimulate PASMCs through other cargo; or free polyamine alone reproduces the EV effect, indicating packaging is irrelevant.  

**Novelty:** Very high – the concept of polyamine‑loaded MK EVs as a vector for vascular remodelling is unprecedented.  

**Weaknesses:** No direct evidence of EV polyamine loading; requires sophisticated EV isolation and metabolic tracing. The hypothesis may prove technically challenging.  

**Priority estimate:**  
- Directional specificity: 4  
- Data support: 3 (indirect)  
- Literature support: 3  
- Novelty: 5  
- Testability: 3  
- Overall: 3.6  

---

### Hypothesis H4  
**Hypothesis ID:** H4  
**Hypothesis title:** Hypoxic lung MKs increase secretion of extracellular vesicles loaded with profibrotic cytokines (PDGF‑BB, TGF‑β1) that drive PASMC hypertrophy and perivascular fibroblast activation.  
**PI instruction addressed:** Extracellular vesicle mechanism grounded in MK biology; uses candidate cargo inferred from literature and general MK function.  
**Core directional hypothesis:** Hypoxia stimulates lung MKs to upregulate and package PDGF‑BB and TGF‑β1 into extracellular vesicles; these EVs are released into the perivascular space where they directly activate PASMCs to proliferate and fibroblasts to differentiate into myofibroblasts, contributing to medial thickening and adventitial fibrosis.  

**Direction‑level reasoning summary:**  
- **Data anchor:** While the metabolomics data show metabolic activation (methionine, lactate, inosine), the accompanying scRNA‑seq dataset contains expression information for Pdgfb and Tgfb1. These are canonical MK/platelet products; prior results establish lung MKs as the pathogenic population. It is plausible that hypoxia enhances their expression.  
- **Biological interpretation:** Hypoxia induces a secretory phenotype in MKs, not only altering metabolism but also upregulating pro‑fibrotic growth factors. EV encapsulation protects these labile proteins and concentrates them at target sites.  
- **MK‑linked enzyme/pathway logic:** PDGF‑BB and TGF‑β1 are potent mitogens for smooth muscle and fibroblasts, respectively; their expression can be driven by HIF‑1α or metabolic stress pathways.  
- **Candidate downstream axis:** Direct vascular‑wall; PDGF‑BB activates PASMC PDGFR‑β, and TGF‑β1 drives fibroblast‑to‑myofibroblast transition and collagen synthesis.  
- **Remodelling logic:** Combined PDGF‑BB/TGF‑β1 action amplifies medial hypertrophy and perivascular fibrosis.  
- **Key uncertainty:** Whether the EV cargo of MKs is altered by hypoxia in a biologically meaningful way, and whether the PDGF‑BB/TGF‑β1 from MK EVs is the dominant source of these factors in the perivascular niche, as other cells also produce them.  

**Directional chain:**  
1. Hypoxia activates HIF‑1α and/or metabolic sensors in lung MKs, upregulating Pdgfb and Tgfb1 transcription.  
2. Newly synthesized PDGF‑BB and TGF‑β1 are packaged into multivesicular bodies and released as exosomes/microvesicles.  
3. EVs accumulate in the perivascular space and bind to PASMCs (PDGFR‑β) and fibroblasts (TGFBR).  
4. PASMCs proliferate and hypertrophy; fibroblasts differentiate into α‑SMA⁺ myofibroblasts and secrete ECM.  
5. Medial thickening, adventitial fibrosis, and vascular stiffness.  

**Candidate downstream axes:**  
- Plausible axes: (1) Direct vascular‑wall – PDGF‑BB on PASMCs; TGF‑β1 on fibroblasts; (2) Indirect – TGF‑β1 may also modulate immune cells.  
- Working model: Both factors acting together on distinct vascular cell types.  
- What remains unresolved: The stoichiometry and timing of PDGF‑BB vs TGF‑β1 release, and whether hypoxia actually increases expression in MKs (requires analysis of the Seurat object).  

**Evidence basis:**  
- **User‑provided data:** The scRNA‑seq object contains Pdgfb and Tgfb1; their expression in MK/platelet population can be queried. The metabolomics data provide indirect evidence of metabolic activation that could fuel protein synthesis.  
- **Public dataset metadata:** GSE289322 may show differential expression of PDGF/TGF‑β pathway genes in PH lung.  
- **Literature:** Platelets and MKs are established sources of PDGF and TGF‑β; hypoxia increases PDGF expression in some contexts.  
- **Biological rationale:** PDGF and TGF‑β are central drivers of vascular remodelling; MKs are anatomically positioned to deliver high local concentrations.  
- **Evidence status:** Hypothetical for MK‑specific hypoxia‑induced upregulation (needs scRNA‑seq validation); strong literature rationale; speculative for EV‑mediated delivery over soluble release.  

**Predicted observations:**  
- In MKs: Upregulated Pdgfb and Tgfb1 mRNA/protein in PH condition.  
- In MK‑EVs: Increased PDGF‑BB and TGF‑β1 protein levels by ELISA/western blot.  
- In tissue: Enhanced phospho‑PDGFR and p‑Smad2/3 signalling in PASMCs and fibroblasts adjacent to MKs.  

**Experimental validation:**  
- **Perturbation:** MK‑specific double knockout of Pdgfb and Tgfb1 (Pf4‑Cre;Pdgfb^(fl/fl);Tgfb1^(fl/fl)) or pharmacological neutralisation of PDGFR‑β and TGF‑β1.  
- **Model:** Chronic hypoxia in mice.  
- **Readout:** Medial thickness, adventitial collagen, fibroblast activation, RVSP.  
- **Expected result:** Combined loss attenuates vascular remodelling.  
- **Falsifying result:** No change in remodelling, or the effect is primarily due to platelet‑derived growth factors, not MK‑specific EV release, indicating MKs are not the critical source.  

**Novelty:** Moderate – MK‑derived EV cargo as drivers of remodelling is an emerging concept, but the specific identification of PDGF‑BB/TGF‑β1 as EV‑enclosed mediators is novel.  

**Weaknesses:** Largely relies on literature; direct user data for Pdgfb/Tgfb1 expression not yet inspected; EVs may carry a multitude of other factors.  

**Priority estimate:**  
- Directional specificity: 3  
- Data support: 2 (needs scRNA‑seq check)  
- Literature support: 4  
- Novelty: 4  
- Testability: 4  
- Overall: 3.4  

---

### Hypothesis H5  
**Hypothesis ID:** H5  
**Hypothesis title:** Hypoxic MKs upregulate purine nucleoside phosphorylase (Pnp), generating inosine that imbalances adenosine receptor signalling and promotes endothelial dysfunction, contributing to vascular remodelling.  
**PI instruction addressed:** Metabolomics‑driven hypothesis; differential metabolite (inosine) → direct compound‑enzyme (Pnp) → MK expression/PH shift → direction‑level vascular axis.  
**Core directional hypothesis:** Hypoxia upregulates Pnp in lung MKs, increasing inosine production; elevated extracellular inosine signals through adenosine A₂ₐ/A₂ᵦ receptors on pulmonary endothelial cells to impair vasodilation, induce a pro‑inflammatory surface, and favour smooth muscle recruitment, thereby facilitating vascular remodelling.  

**Direction‑level reasoning summary:**  
- **Data anchor:** Inosine is upregulated 3.82‑fold in PH MKs. Pnp is expressed in 20.31% MKs and significantly upregulated in PH MKs (log2FC 1.74, Wilcoxon p=3.81×10⁻⁶).  
- **Biological interpretation:** Enhanced purine degradation in hypoxic MKs generates inosine, which can be released and act as a partial adenosine receptor agonist.  
- **MK‑linked enzyme/pathway logic:** Pnp catalyses the reversible phosphorolysis of inosine to hypoxanthine, but under substrate accumulation it may produce inosine; its upregulation aligns with inosine accumulation.  
- **Candidate downstream axis:** Direct vascular‑wall (endothelial) – activation of endothelial A₂ receptors can impair NO production, increase adhesion molecules, and promote a pro‑vasoconstrictive, leaky phenotype. Immune‑mediated effects (adenosine signalling on T cells, macrophages) are possible but not primary.  
- **Remodelling logic:** Chronic endothelial activation leads to intimal hyperplasia, leukocyte adhesion, and PASMC hypertrophy – all hallmarks of hypoxia‑induced remodelling.  
- **Key uncertainty:** The net effect of inosine on adenosine receptor signalling is complex and can be protective or pathological; the hypothesis requires that inosine acts as a pathological signal in this context.  

**Directional chain:**  
1. Hypoxia upregulates Pnp in MKs, favouring nucleoside salvage/degradation.  
2. Increased inosine production and release from MKs.  
3. Inosine binds with low affinity to endothelial A₂ receptors, causing sustained, moderate activation.  
4. Chronic A₂ signalling impairs endothelial nitric oxide synthase (eNOS) and upregulates VCAM‑1/ICAM‑1, promoting monocyte adhesion and reducing vasodilatory capacity.  
5. Endothelial dysfunction contributes to smooth muscle proliferation and medial thickening.  

**Candidate downstream axes:**  
- Plausible axes: (1) Direct endothelial activation – A₂‑mediated dysfunction; (2) Immune‑mediated – adenosine/inosine modulation of T‑cell and macrophage function; (3) Direct PASMC – inosine may have weak mitogenic effects.  
- Working model: Endothelial activation as the primary initiator of remodelling.  
- What remains unresolved: Whether MK‑derived inosine achieves the required local concentration, and the net A₂R signalling outcome (pro‑ vs anti‑remodelling).  

**Evidence basis:**  
- **User‑provided data:** Inosine up in MKs (sFig6A, log2FC 3.82); Pnp expression, enrichment (log2 −1.22, but PH‑up 1.74 with p=3.81×10⁻⁶) in MKs.  
- **Public dataset metadata:** GSE289322 could be queried for Pnp and adenosine pathway gene expression.  
- **Literature:** Inosine has immunomodulatory and vasoactive properties; adenosine signalling is implicated in PH pathogenesis.  
- **Biological rationale:** Purine metabolism is altered in hypoxia and can influence vascular tone.  
- **Evidence status:** Direct for metabolite and enzyme; inferred for endothelial A₂R activation; speculative for net pathological effect.  

**Predicted observations:**  
- In MKs: Increased Pnp protein and inosine secretion.  
- In tissue: Elevated inosine in lung lavage; increased endothelial VCAM‑1/ICAM‑1 expression; impaired endothelial‑dependent vasodilation.  
- In metabolomics: Altered adenosine/inosine ratio in lung tissue.  

**Experimental validation:**  
- **Perturbation:** MK‑specific deletion of Pnp (Pf4‑Cre;Pnp^(fl/fl)).  
- **Model:** Chronic hypoxia; assess at early and late timepoints.  
- **Readout:** Endothelial function (acetylcholine‑induced relaxation), endothelial activation markers, medial thickness, RVSP.  
- **Expected result:** Pnp knockout prevents inosine increase and endothelial dysfunction, attenuating remodelling.  
- **Falsifying result:** No effect on endothelial function or remodelling, or inosine acts only on immune cells, indicating the endothelial axis is not causal.  

**Novelty:** Moderate – metabolite‑mediated endothelial dysfunction from MKs is a fresh angle.  

**Weaknesses:** Complex adenosine biology; inosine may have protective effects via A₂ receptors; the hypothesis could be falsified if inosine is rapidly cleared or converted.  

**Priority estimate:**  
- Directional specificity: 3  
- Data support: 4  
- Literature support: 3  
- Novelty: 4  
- Testability: 3  
- Overall: 3.4  

---

### Self‑filtered rejected ideas:
- A pure “MK‑derived platelet thrombo‑inflammatory” hypothesis was rejected because it lacked a specific metabolic or EV cargo data anchor and fell into generic platelet activation.  
- An AMD1‑Th17‑IL‑17‑EndMT bridge was excluded because the evidence does not directly support that level of resolution; the same metabolic direction is captured in H1 with broader candidate axes.  
- Hypotheses based solely on public dataset GSE289322 without user data anchor were avoided to maintain grounding.  

### Requests for Tool Use Agent:
- Query the Seurat object for expression of Pdgfb, Tgfb1, Rab27a, Tsg101, and Cd44 (EV‑related) in the MK/platelet population, comparing PH vs control, to strengthen H4 and future EV hypotheses.  
- Analyse the GSE289322 de‑results for differential expression of Amd1, Ldha, Pnp, and Amd2 to validate tissue‑level support.

## generation_3
Cycle ID: 1

## Hypotheses generated
H1, H2, H3, H4

---

### Hypothesis ID: H1
**Hypothesis title:** AMD1-driven polyamine metabolism in hypoxic MKs promotes perivascular ECM cross-linking and stiffening.

**PI instruction addressed:** Metabolomics‑driven mechanism; ECM and spatial niche thrombo‑inflammatory remodelling.

**Core directional hypothesis:**
Hypoxic up‑regulation of AMD1 in lung megakaryocytes redirects methionine toward polyamine (spermidine/spermine) synthesis, and these polyamines serve as substrates for transglutaminase‑mediated matrix cross‑linking or hypusination‑dependent profibrotic gene expression, thereby increasing perivascular matrix stiffness and contributing to medial thickening and muscularization.

**Direction‑level reasoning summary:**
- Data anchor: Methionine is strongly elevated in PH MKs (log2FC = 3.26); AMD1, the rate‑limiting enzyme for polyamine synthesis, is significantly enriched in MKs (1.35‑fold) and further up‑regulated in PH (log2FC = 1.77, p = 6.55e‑06).  
- Biological interpretation: Hypoxia drives a methionine‑salvage/polyamine metabolic programme in lung MKs, creating a local pool of spermidine and spermine that can be secreted or incorporated into downstream effector pathways.  
- MK‑linked enzyme/pathway logic: AMD1 converts S‑adenosylmethionine into decarboxylated SAM for polyamine biosynthesis; its clear MK enrichment and hypoxia responsiveness make it a plausible source of polyamines in the perivascular niche.  
- Candidate downstream axis: ECM/stromal (direct vascular‑wall) – polyamines are essential co‑substrates for transglutaminase 2 (TGM2)‑catalyzed collagen and fibronectin cross‑linking and for hypusination of eIF5A, which drives translation of pro‑fibrotic transcripts.  
- Remodelling logic: Enhanced matrix cross‑linking and myofibroblast‑like activation increase vessel wall stiffness, reduce compliance, and promote medial thickening.  
- Key uncertainty: Whether the polyamine pool generated by MK AMD1 acts locally in the perivascular ECM versus acting through a cell‑autonomous MK programme; the relative contribution of TGM2‑mediated cross‑linking versus eIF5A‑hypusination‑dependent gene expression remains unresolved but both are consistent with the metabolic shift.

**Directional chain:**
1. Hypoxia up‑regulates AMD1 and methionine‑derived polyamine synthesis in lung MKs.
2. MK‑generated polyamines (spermidine, spermine) are released into the perivascular microenvironment.
3. Polyamines serve as substrates for transglutaminase‑catalysed ECM cross‑linking and/or for eIF5A hypusination in vascular fibroblasts/SMCs, promoting a pro‑fibrotic, stiffening programme.
4. Broad cellular response: enhanced collagen/fibronectin cross‑linking, fibroblast activation, SMC hypertrophy/hyperplasia.
5. Contribution to remodeling phenotype: vascular stiffening, medial thickening, and muscularization.

**Candidate downstream axes:**
- Plausible axes: (i) Transglutaminase‑2 (TGM2)‑mediated ECM protein cross‑linking; (ii) eIF5A hypusination driving translation of pro‑fibrotic genes (e.g., collagen, LOX); (iii) Polyamine‑dependent regulation of vascular smooth muscle cell proliferation; (iv) Polyamine‑modulated immune cell (macrophage) production of profibrotic factors.
- Working model: The dominant ECM‑remodelling effect is via TGM2 cross‑linking of matrix proteins in the immediate perivascular space, which directly stiffens the vessel wall. Hypusination‑dependent gene programmes in adjacent fibroblasts or SMCs reinforce the stromal response.
- Specific examples, if useful: Spermidine is the substrate for deoxyhypusine synthase, which post‑translationally modifies eIF5A; spermidine/spermine are also Co‑substrates for TGM2 cross‑linking of collagen I.
- What remains unresolved: Whether the polyamines that cross‑link ECM originate from MK secretion or from MK‑derived extracellular vesicles; the exact cell type(s) in the vessel wall that incorporate polyamines to drive cross‑linking (pericytes, fibroblasts, SMC); whether hypusination‑regulated transcripts are the dominant effect.

**Evidence basis:**
- User‑provided data: sFig6A metabolomics – methionine up in PH MKs (log2FC = 3.26); AMD1 mRNA in scRNA‑seq – MK enrichment 1.35‑fold, PH‑vs‑control MK log2FC = 1.77, p = 6.55e‑06.
- Public dataset metadata or analyzed public data: Not yet examined; GSE289322 (lung PH vs control) could validate AMD1 differential expression and polyamine pathway enrichment in tissue.
- Literature: AMD1 and polyamines are implicated in cancer‑associated fibrosis and vascular stiffness; TGM2 and eIF5A hypusination are known mediators of matrix remodelling.
- Biological rationale: Polyamines are obligate for ECM cross‑linking and translation of a subset of pro‑fibrotic transcripts; a hypoxia‑driven polyamine surge from perivascular MKs directly feeds this niche.
- Evidence status: Direct for the methionine→AMD1 axis in MKs; indirect/inferred for polyamine secretion and ECM cross‑linking; speculative for the relative role of TGM2 vs hypusination.

**Predicted observations:**
- In MKs: Elevated AMD1 protein, spermidine/spermine levels in PH MKs; increased polyamine‑containing EVs.
- In recipient or tissue compartment: Perivascular accumulation of cross‑linked collagen (resistant to acid extraction) and hypusinated eIF5A in adventitial fibroblasts or SMCs.
- In metabolomics or pathway activity: Increased putrescine/spermidine in lung tissue of PH mice that is MK‑dependent (reduced in TPOR‑/‑ chimeras with lung MK deficiency).

**Experimental validation:**
- Perturbation: MK‑specific Amd1 knockout (Amd1^fl/fl Pf4‑Cre or similar) or pharmacological AMD1 inhibition (e.g., SAM486) in mice.
- Model: Hypoxic PH model (hypoxia‑exposed mice) with lung‑resident MKs competent or deficient for AMD1.
- Readout: Vascular stiffness (pressure‑volume curves), medial thickness, collagen cross‑linking (hydroxyproline, pyridinoline), ECM ultrastructure, and hypusinated eIF5A levels.
- Expected result: AMD1 deficiency reduces polyamine levels in lung tissue, decreases ECM cross‑linking and vascular stiffness, and attenuates medial thickening.
- Falsifying result: AMD1 inhibition does not alter lung polyamine content or ECM cross‑linking, or no vascular remodelling protection is seen despite reduced MK polyamines.

**Novelty:** First link of MK‑derived polyamine metabolism to perivascular ECM cross‑linking in hypoxic pulmonary hypertension; identifies AMD1 as a MK‑expressed enzyme with direct ECM remodelling potential beyond its classical role in cell proliferation.

**Weaknesses:** The mechanism by which MK polyamines reach the ECM is not resolved; alternative AMD1‑dependent polyamine functions (immune modulation, EV cargo) may be equally or more important. The hypothesis assumes polyamines are secreted; direct proof of polyamine export from MKs is lacking.

**Revision relative to previous cycle:** New hypothesis.

**Priority estimate:**
- Directional specificity: 4
- Data support: 5 (strong metabolomics and transcriptomics)
- Literature support: 3 (fibrosis but not MK-specific PH)
- Novelty: 5
- Testability: 4 (MK‑specific genetic tools available but ECM readouts require careful timing)
- Overall generation priority: 4

**Explicit rejection filter:** Passes all.

---

### Hypothesis ID: H2
**Hypothesis title:** Hypoxic MK purine degradation generates an adenosine/inosine‑rich niche that promotes thrombo‑inflammatory vascular remodelling through endothelial and immune adenosine receptors.

**PI instruction addressed:** Metabolomics‑driven; thrombo‑inflammatory and immune remodelling.

**Core directional hypothesis:**
Elevated inosine in hypoxic MKs reflects enhanced purine nucleotide salvage/degradation (via PNP/NT5C2), leading to accumulation of adenosine and inosine in the perivascular space where adenosine activates A2B receptors on endothelial cells and infiltrating myeloid cells, driving endothelial activation, pro‑coagulant surface expression, and cytokine release that together promote medial muscularization and vascular remodelling.

**Direction‑level reasoning summary:**
- Data anchor: Inosine is up in PH MKs (log2FC = 3.82); the purine degrading enzyme PNP is expressed in MKs (20 % of MKs) and significantly upregulated in PH MKs (log2FC = 1.74, p = 3.81e‑06). NT5C2, another purine nucleotidase, also shows a strong PH‑up signature (log2FC = 2.88, p = 2e‑04).  
- Biological interpretation: Hypoxia drives a purine salvage/degradation programme in MKs that raises extracellular inosine/adenosine; adenosine is a potent vasoactive and immunomodulatory signalling molecule.  
- MK‑linked enzyme/pathway logic: PNP and NT5C2 are key enzymes that convert purine nucleotides to nucleosides; their PH induction in MKs indicates MKs become a source of adenosine/inosine in the hypoxic lung.  
- Candidate downstream axis: Thrombo‑inflammatory / immune‑mediated – adenosine signalling on vascular endothelial cells up‑regulates tissue factor (F3), adhesion molecules, and chemokines, while on monocytes/macrophages it can promote a pro‑fibrotic M2‑like phenotype.  
- Remodelling logic: Adenosine‑A2B receptor activation on endothelium promotes a pro‑coagulant surface (tissue factor, phosphatidylserine exposure) and increases leukocyte adhesion, fostering local fibrin deposition and immune cell recruitment that amplify medial smooth muscle activation and muscularization.  
- Key uncertainty: Whether the adenosine generated by MKs reaches effective concentrations in the perivascular niche and whether A2B receptor‑dependent thrombo‑inflammatory signalling dominates over vasodilatory A2A effects.

**Directional chain:**
1. Hypoxia up‑regulates PNP/NT5C2 in lung MKs, increasing extracellular inosine and adenosine.
2. Adenosine binds A2B (and possibly A2A) receptors on adjacent pulmonary microvascular endothelial cells and recruited myeloid cells.
3. A2B signalling triggers tissue factor up‑regulation, endothelial leukocyte adhesion molecule expression, and production of pro‑inflammatory cytokines (e.g., IL‑6, CCL2), creating a localized thrombo‑inflammatory microenvironment.
4. Fibrin deposition and myeloid‑derived growth factors stimulate smooth muscle cell proliferation and hypertrophy.
5. Contributes to medial thickening, muscularization, and endothelial dysfunction.

**Candidate downstream axes:**
- Plausible axes: (i) Adenosine‑A2B–endothelial tissue factor pathway (thrombo‑inflammatory); (ii) Adenosine‑A2B–monocyte/macrophage profibrotic activation (immune‑mediated); (iii) Inosine as a metabolic intermediate that feeds back into polyamine or one‑carbon metabolism (metabolic coupling).
- Working model: The dominant acute effect is adenosine‑A2B–driven endothelial pro‑coagulant switch, which sparks fibrin formation and leukocyte recruitment; chronic activation sustains immune‑driven remodelling.
- What remains unresolved: Direct proof that MK‑derived adenosine reaches endothelial A2B receptors in vivo; the relative contribution of adenosine versus inosine signalling (inosine may act via A3 or adenosine after salvage).

**Evidence basis:**
- User‑provided data: sFig6A metabolomics – inosine up in PH MKs (log2FC = 3.82); scRNA‑seq – PNP PH‑vs‑control MK log2FC = 1.74, p = 3.81e‑06; NT5C2 log2FC = 2.88, p = 2e‑04.
- Public dataset metadata or analyzed public data: GSE289322 may show up‑regulation of PNP, NT5C, or adenosine‑pathway genes in PH lung tissue; can be checked.
- Literature: Adenosine signalling is well documented in pulmonary hypertension and thrombo‑inflammation; hypoxia is known to induce CD73 and adenosine production; A2B receptor knockout attenuates PH in some models.
- Biological rationale: MKs are ideally positioned perivascularly to release purine nucleosides directly onto endothelial cells; ecto‑5’‑nucleotidase (CD73) on endothelial cells can convert MK‑derived AMP/ADP to adenosine.
- Evidence status: Direct for inosine elevation and PNP/NT5C2 up‑regulation in MKs; indirect for adenosine signalling and thrombo‑inflammatory outcome; speculative that MK‑derived adenosine is the main source versus endothelial‑derived adenosine.

**Predicted observations:**
- In MKs: Elevated adenosine/inosine release in conditioned medium from PH MKs.
- In recipient or tissue compartment: Perivascular tissue factor expression, fibrin(ogen) deposition, and myeloid cell infiltration dependent on adenosine A2B receptor activity.
- In metabolomics or pathway activity: Elevated adenosine in lung tissue of hypoxic mice that is reduced when lung MKs are depleted (e.g., TPOR‑/‑ chimeras).

**Experimental validation:**
- Perturbation: MK‑specific knockdown of Pnp or Nt5c2 (or broad adenosine pathway block with A2B antagonist PSB1115 or adenosine deaminase overexpression).
- Model: Hypoxic PH in mice; compare MK purine flux versus endothelial‑derived adenosine by using CD39/CD73 inhibitors.
- Readout: Tissue factor expression, fibrin deposition, vascular remodelling parameters.
- Expected result: Blocking MK purine generation or A2B signalling reduces thrombo‑inflammatory markers and attenuates muscularization.
- Falsifying result: Adenosine receptor blockade does not alter vascular remodelling or thrombotic indices despite reduced purine metabolites from MKs.

**Novelty:** Redirects attention from endothelial‑derived adenosine to a MK‑specific purine source in the hypoxic lung; couples MK metabolism to classic thrombo‑inflammatory adenosine pathway.

**Weaknesses:** Extracellular adenosine concentrations depend on equilibrative transporters and ectonucleotidases; the hypothesis assumes MKs release sufficient adenosine/inosine to dominate the perivascular pool. The vasodilator action of adenosine could counteract remodelling in some contexts, making the net effect condition‑dependent.

**Revision relative to previous cycle:** New hypothesis.

**Priority estimate:**
- Directional specificity: 4
- Data support: 4 (metabolomics and transcriptomics, but adenosine itself not measured)
- Literature support: 4 (adenosine in PH well studied)
- Novelty: 4
- Testability: 4
- Overall generation priority: 4

**Explicit rejection filter:** Passes all.

---

### Hypothesis ID: H3
**Hypothesis title:** Hypoxic lung MKs release tissue‑factor‑positive extracellular vesicles that initiate perivascular coagulation, creating a fibrin‑rich scaffold for immune cell recruitment and smooth muscle activation.

**PI instruction addressed:** Thrombo‑inflammatory and spatial‑niche mechanism; ECM and immune remodelling.

**Core directional hypothesis:**
Hypoxia induces MKs to produce and release phosphatidylserine‑exposing, tissue‑factor‑bearing extracellular vesicles (EVs), which trigger local thrombin generation and fibrin deposition in the perivascular space; the provisional fibrin matrix then captures circulating monocytes and provides a pro‑proliferative signal to vascular smooth muscle cells, thereby driving medial thickening and muscularization.

**Direction‑level reasoning summary:**
- Data anchor (indirect): The prior‑results document establishes that lung‑resident MKs are essential for hypoxia‑induced vascular remodelling; scRNA‑seq confirms a distinct MK/platelet cluster in the lung. MKs are known hematologic sources of tissue factor (TF) and pro‑coagulant EVs upon stimulation.  
- Biological interpretation: In the hypoxic perivascular niche, MKs adopt a “pro‑coagulant” phenotype, shedding EVs that disseminate TF and anionic phospholipids, converting the immediate microenvironment into a thrombin‑generating compartment.  
- MK‑linked enzyme/pathway logic: TF (F3) expressed in MKs binds factor VIIa to initiate the extrinsic coagulation cascade; phosphatidylserine on EV surfaces provides the platform for prothrombinase complex assembly. The end product, thrombin, also cleaves protease‑activated receptors (PARs) on SMCs and fibroblasts, linking coagulation to remodelling.  
- Candidate downstream axis: Thrombo‑inflammatory / EV‑stromal – fibrin matrix serves as a provisional scaffold for monocyte/macrophage adhesion and differentiation, while thrombin‑PAR signaling directly promotes SMC proliferation and migration.  
- Remodelling phenotype: Fibrin deposition thickens the vessel wall, recruits immune cells that sustain inflammation, and thrombin‑PAR activation drives SMC hyperplasia → medial thickening and muscularization.  
- Key uncertainty: Whether hypoxia actually induces TF expression in lung MKs and whether MK‑derived EVs carry sufficient TF to overcome endogenous anticoagulant systems in vivo; the relative contribution of fibrin‑mediated trapping of immune cells versus direct thrombin‑PAR remodelling remains unresolved.

**Directional chain:**
1. Hypoxia up‑regulates tissue factor (F3) and EV shedding in lung MKs.
2. MK‑derived TF‑positive EVs bind factor VIIa and assemble prothrombinase, generating thrombin that deposits fibrin locally.
3. Fibrin matrix entraps circulating monocytes and provides adhesion sites; thrombin activates PAR‑1 on SMCs and fibroblasts.
4. Recruited monocytes differentiate into macrophages that release pro‑fibrotic factors, while thrombin‑stimulated SMCs proliferate and hypertrophy.
5. Leads to perivascular fibrin accumulation, immune cell infiltration, medial thickening, and muscularization.

**Candidate downstream axes:**
- Plausible axes: (i) TF‑EV → thrombin → fibrin scaffold → monocyte entrapment → M2‑like profibrotic activity; (ii) Thrombin → PAR‑1 on SMCs → proliferation/hypertrophy; (iii) Fibrin degradation products (D‑dimers) → pro‑angiogenic and pro‑inflammatory signals.
- Working model: The initial MK‑EV‑driven coagulation burst creates a fibrin‑rich niche that physically traps immune cells and feeds back to sustain SMC activation, coupling thrombotic micro‑events to chronic vascular remodelling.
- What remains unresolved: Direct demonstration that lung MKs express TF (F3) under hypoxia; whether MK‑EVs contain additional remodelling cargo (e.g., PDGF, TGF‑β) that amplifies the effect; the spatial extent of fibrin deposition around small pulmonary vessels.

**Evidence basis:**
- User‑provided data: Prior‑results document shows lung‑resident MKs drive PH vascular remodelling; scRNA‑seq confirms MK/platelet population. MK metabolomics (sFig6A) and tissue metabolomics (Figure6D+F) were not designed to capture coagulation. No direct user data on TF expression or EV cargo.  
- Public dataset metadata or analyzed public data: GSE289322 (lung PH vs control) could be mined for F3, PAR1 (F2r), and coagulation pathway enrichment; GSE291455 could check baseline expression. Neither provides MK‑specificity.
- Literature: Megakaryocytes are known to express TF and release pro‑coagulant EVs (microparticles). Hypoxia induces TF expression in endothelial cells and monocytes; less is known in MKs. Thrombin and PAR signalling are established drivers of SMC proliferation in vascular injury and PH.
- Biological rationale: Platelets, the progeny of MKs, are a major source of circulating TF‑positive EVs; MKs in the lung could shed pro‑coagulant EVs directly into the perivascular space without entering the circulation, creating a local coagulation circuit.
- Evidence status: Speculative for MK‑specific TF up‑regulation and EV shedding; directly testable by checking F3 expression in the scRNA‑seq data and by in vitro hypoxic MK EV experiments.

**Predicted observations:**
- In MKs: Up‑regulation of F3 mRNA/protein and increased TF‑positive EV release under hypoxia.
- In recipient or tissue compartment: Perivascular fibrin deposition and D‑dimer levels in lung tissue of hypoxic mice that are reduced in TPOR‑/‑ or lung‑MK‑deficient chimeras; co‑localization of MK‑derived EVs (e.g., CD41+ TF+) with fibrin.
- In metabolomics or pathway activity: Not directly assessed by current metabolomics; could detect thrombin activity via fluorogenic assays or by fibrinopeptide A.

**Experimental validation:**
- Perturbation: MK‑specific F3 knockout (F3^fl/fl Pf4‑Cre) or pharmacological TF inhibition (e.g., recombinant TFPI, anti‑TF antibody); or inhibit EV biogenesis (e.g., GW4869, nSMase inhibitor).
- Model: Hypoxic PH in mice; also in vitro generation of MK‑derived EVs from lung MKs under hypoxia.
- Readout: Fibrin deposition (Martius Scarlet Blue staining), EV enumeration (nanoparticle tracking), thrombin‑antithrombin complexes, vascular wall thickness, and muscularization.
- Expected result: TF‑deficient MKs or blocked EV release reduces fibrin, immune cell accumulation, and vascular remodelling.
- Falsifying result: No fibrin deposition is observed around pulmonary vessels in PH, or MK‑EV blockade does not alter remodelling despite effective ablation of TF+ EVs.

**Novelty:** Introduces an MK‑centric thrombotic initiation mechanism for pulmonary vascular remodelling, bridging platelet precursor biology with pro‑coagulant EV biology in the hypoxic lung niche.

**Weaknesses:** No direct user data on TF or EV production by lung MKs; hypothesis depends heavily on extrapolation from platelet biology and general hypoxia‑EV biology. Potential confounding from platelet‑derived EVs cannot be distinguished from MK‑derived EVs without specific lineage tracing.

**Revision relative to previous cycle:** New hypothesis.

**Priority estimate:**
- Directional specificity: 3
- Data support: 2 (prior data support MK role, but no direct TF/EV data)
- Literature support: 4 (TF-EV thrombo-inflammatory axis established in cancer and sepsis)
- Novelty: 5
- Testability: 4
- Overall generation priority: 3

**Explicit rejection filter:** Passes all; includes MK-specific component (hypoxia-dependent TF/EV), thrombosis-mediated vascular remodelling, and testable by MK-specific knockout.

---

### Hypothesis ID: H4
**Hypothesis title:** Hypoxic MKs secrete thrombospondin‑1 (TSP‑1) that activates latent TGF‑β in the perivascular space, driving myofibroblast differentiation and extracellular matrix deposition.

**PI instruction addressed:** ECM and immune remodelling; spatial niche mechanism through a latent cytokine activation.

**Core directional hypothesis:**
Hypoxia up‑regulates thrombospondin‑1 in lung megakaryocytes; secreted TSP‑1 binds to the latency‑associated peptide of TGF‑β stored in the perivascular matrix, releasing active TGF‑β that converts local fibroblasts and pericytes into myofibroblasts and stimulates excessive collagen production, leading to vascular stiffening and medial thickening.

**Direction‑level reasoning summary:**
- Data anchor: The prior results establish that lung‑resident MKs are necessary for hypoxia‑induced vascular remodelling and perivascular fibrosis. While scRNA‑seq expression data for Thbs1 are not directly extracted here, Mk/platelet cells are present and can be queried. Tissue metabolomics and prior knowledge show a fibrotic phenotype in hypoxic lungs.  
- Biological interpretation: TSP‑1 is a major MK‑ and platelet‑derived matricellular protein that is rapidly released upon activation; it is a potent activator of latent TGF‑β, the master fibrogenic cytokine. Hypoxia is a known inducer of TSP‑1 in many cell types.  
- MK‑linked enzyme/pathway logic: TSP‑1 contains a KRFK sequence that interacts with the LAP of TGF‑β, releasing the active dimer. This bypasses the need for integrin‑mediated activation and delivers a concentrated pulse of active TGF‑β directly adjacent to vascular stromal cells.  
- Candidate downstream axis: ECM/stromal (direct vascular‑wall) – active TGF‑β induces fibroblast‑to‑myofibroblast transition, up‑regulates collagen I/III and fibronectin, and drives CTGF expression, all contributing to perivascular fibrosis.  
- Remodelling phenotype: Increased collagen deposition, adventitial fibrosis, vascular stiffening, and ultimately medial thickening and muscularization through matrix‑driven mechanosignalling.  
- Key uncertainty: Whether lung MKs express high levels of Thbs1 under hypoxia; whether TSP‑1‑mediated TGF‑β activation is the dominant source of active TGF‑β in the perivascular niche or whether other activators (integrins, proteases) are more important.

**Directional chain:**
1. Hypoxia induces TSP‑1 expression and secretion by lung MKs.
2. TSP‑1 binds and activates latent TGF‑β sequestered in the perivascular ECM.
3. Active TGF‑β diffuses to adjacent fibroblasts, pericytes, and smooth muscle cells, triggering Smad‑dependent and Smad‑independent profibrotic transcriptional programmes.
4. Fibroblasts and pericytes differentiate into α‑SMA‑expressing myofibroblasts that deposit excess collagen and stiffen the vessel wall.
5. Contributes to medial thickening, muscularization, and vascular stiffness.

**Candidate downstream axes:**
- Plausible axes: (i) TSP‑1 → TGF‑β → Smad2/3 → myofibroblast differentiation and ECM production; (ii) TSP‑1 → CD47 → endothelial regulation of NO/cGMP (counter‑regulatory); (iii) TGF‑β → inhibition of MMPs / induction of TIMPs, further stabilizing the ECM.
- Working model: The principal pathway is TSP‑1–mediated TGF‑β activation, which directly fuels a fibrotic niche; the CD47 axis may modulate endothelial function but is secondary.
- What remains unresolved: Whether TSP‑1 from MKs is sufficient to release TGF‑β in the presence of other extracellular binding proteins; whether the effect requires MK proximity to ECM‑stored latent TGF‑β (spatial niche dependency) or if MK‑derived TSP‑1 acts systemically.

**Evidence basis:**
- User‑provided data: Prior results demonstrate lung‑MK‑dependent fibrosis and vascular remodelling; scRNA‑seq MK/platelet cluster exists. Metabolomics does not directly address TSP‑1.  
- Public dataset metadata or analyzed public data: GSE289322 can be scanned for Thbs1 and Tgfb1 pathway gene expression; GSE291455 provides baseline. This could provide lung‑level support but not MK specificity.
- Literature: Platelets and MKs are the major source of TSP‑1; TSP‑1 is a well‑characterized TGF‑β activator in wound healing and fibrosis. Hypoxia induces TSP‑1 in endothelial cells and fibroblasts; MK‑specific expression under hypoxia is less documented. TGF‑β signalling is a central pathway in pulmonary arterial hypertension and vascular fibrosis.
- Biological rationale: MKs residing in the perivascular space are ideally positioned to deposit TSP‑1 directly onto the adventitial matrix, spatially confined to small muscularized pulmonary vessels where fibrosis‑driven remodelling occurs.
- Evidence status: Inferred from general MK biology and PH fibrosis; direct evidence of MK Thbs1 expression and hypoxia‑induction requires validation from the scRNA‑seq data.

**Predicted observations:**
- In MKs: Up‑regulated Thbs1 mRNA and protein in PH MKs; increased secretion of TSP‑1 in conditioned medium.
- In recipient or tissue compartment: Perivascular accumulation of active TGF‑β (phospho‑Smad2/3) and α‑SMA‑positive myofibroblasts surrounding small vessels that is reduced upon MK depletion.
- In metabolomics or pathway activity: Not captured.

**Experimental validation:**
- Perturbation: MK‑specific Thbs1 deletion (Thbs1^fl/fl Pf4‑Cre) or pharmacological TSP‑1 blocking peptide (LSKL); TGF‑β neutralising antibody or ALK5 inhibitor to confirm downstream role.
- Model: Hypoxic PH in mice; in vitro co‑culture of hypoxic lung MKs with lung fibroblasts.
- Readout: Active TGF‑β levels, α‑SMA+ myofibroblast numbers, collagen deposition, vascular stiffness, medial thickness.
- Expected result: Loss of MK TSP‑1 reduces active TGF‑β and attenuates fibrotic vascular remodelling.
- Falsifying result: MK‑specific Thbs1 knockout does not alter TGF‑β activity or fibrosis despite efficient deletion; other TSP‑1 sources (platelets, macrophages) compensate.

**Novelty:** Identifies MK‑derived TSP‑1 as a specific TGF‑β actuator in the hypoxic pulmonary perivascular niche, shifting focus from circulating platelets to tissue‑resident megakaryocytes as fibrotic initiators.

**Weaknesses:** No direct scRNA‑seq expression data provided; must be verified. TSP‑1 also has anti‑angiogenic properties that could oppose remodelling in certain contexts; net effect may be context‑dependent.

**Revision relative to previous cycle:** New hypothesis.

**Priority estimate:**
- Directional specificity: 4
- Data support: 2 (prior MK remodelling role, no direct Thbs1 data)
- Literature support: 4 (well‑established TSP‑1/TGF‑β fibrotic axis)
- Novelty: 4
- Testability: 4
- Overall generation priority: 3

**Explicit rejection filter:** Passes all; MK‑specific (Thbs1 expression), hypoxia‑dependent, vascular remodelling via fibrosis, testable.

---

## Self‑filtered rejected ideas:
- **MK‑derived IL‑6 driving Th17-like immune remodelling:** Rejected because no user metabolomics or transcriptomics data directly support MK IL‑6 up‑regulation; the metabolic link would over‑resolve a T‑cell subset without evidence, and the PI instruction warns against that.
- **MK‑derived lactate acidosis driving immune suppression:** A lactate‑based hypothesis was considered because glycolysis likely shifts in hypoxic MKs, but the metabolomics shortlist and mechanism‑ready chains did not prioritize lactate or LDHA; only one glycolytic metabolite (pyruvaldehyde) appears without an obvious enzyme‑MK‑remodelling chain, making it too speculative without further data extraction. A generation agent should not fabricate a Ldha link when not in the Evidence Context.
- **MK‑derived CXCL12 recruiting progenitor cells:** Rejected because no differential expression data or pathway enrichment was presented; it would be a gene-list-based hypothesis without a data anchor, and the PI brief requires data-grounded generation.

## Requests for Tool Use Agent:
- Query the Seurat object (`seurat_merged.rds`) to retrieve expression and differential expression for `Amd1`, `Pnp`, `Nt5c2`, `F3`, `Thbs1`, `Lox`, `Loxl1`, `Loxl2` in the MK/platelet cluster versus all other cells, and PH vs control within MKs.  
- Examine the `candidate_gene_check.tsv` and `de_results.tsv` files from GSE289322 for these genes and for polyamine pathway, purine metabolism, coagulation, and TGF‑β pathway enrichment.  
- Check tissue metabolomics (Figure6D+F) for spermidine, spermine, adenosine, inosine, and fibrinopeptide‑related peaks.  
- Perform gene set enrichment on GSE289322 DE results using KEGG pathways: mmu00480 (Glutathione metabolism, to pick up polyamine?), mmu00270 (Cysteine and methionine metabolism), mmu00230 (Purine metabolism), mmu04610 (Complement and coagulation cascades).
